var title_f26_38_27232="Multifocal atrial tachycardia - two month old infant";
var content_f26_38_27232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Chaotic (multifocal) atrial tachycardia - two month old infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 126px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A rhythm strip from a two month old with chaotic (multifocal) atrial tachycardia. The numerals represent the different P wave morphologies, when discernible demonstrating the different foci.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27232=[""].join("\n");
var outline_f26_38_27232=null;
var title_f26_38_27233="Lymph node enlargement CT";
var content_f26_38_27233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Supraclavicular lymph node enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows left (left panel) and right (right panel) supraclavicular node enlargement (N) in patients with bronchogenic carcinoma. Spread to the supraclavicular lymph nodes indicates N3 involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27233=[""].join("\n");
var outline_f26_38_27233=null;
var title_f26_38_27234="Patient information: Kidney stones in children (The Basics)";
var content_f26_38_27234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17221\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"         Anatomy of the urinary tract in children",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/59/23474\">",
"         Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/51/17202\">",
"         Patient information: Blood in the urine (hematuria) in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/56/43905\">",
"         Patient information: Kidney stones in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/53/28499\">",
"         Patient information: Kidney stones in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/26/15779\">",
"         Patient information: Kidney stones in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Kidney stones in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/kidney-stones-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10104466\">",
"      <span class=\"h1\">",
"       What are kidney stones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Kidney stones are just what they sound like: small stones that form in the kidneys and urinary tract. The urinary tract is a group of organs that includes the ureter, bladder, and urethra (",
"      <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Kidney stones are made of salts and minerals that are normally in the urine. Sometimes, these salts and minerals clump together and form small stones. Children can get kidney stones, just as adults can.",
"     </p>",
"     <p>",
"      Kidney stones are usually carried out of the body when a child urinates. But sometimes a kidney stone gets stuck on the way out. If this happens, the child can have pain, blood in the urine, and other symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10104481\">",
"      <span class=\"h1\">",
"       What are the symptoms of kidney stones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the belly or back",
"       </li>",
"       <li>",
"        Blood in the urine, which can make urine pink or red",
"       </li>",
"       <li>",
"        Pain when the child urinates",
"       </li>",
"       <li>",
"        The need to urinate in a hurry",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Being irritable and crying when urinating (in small children)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some children with kidney stones do not have any symptoms. In these children, doctors often find the kidney stones by accident. This can happen if a child has an imaging test, such as an X-ray, for another reason.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10104496\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child has the symptoms listed above, take him or her to the doctor or nurse as soon as possible. Kidney stones can block urine flow and cause infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10104511\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will do an exam and order tests on a sample of your child&rsquo;s urine. He or she will also order an imaging test, such as a CT scan, ultrasound, or X-ray. Imaging tests create pictures of the inside of the body. They can show if a kidney stone is causing the symptoms. If your child has a stone, imaging tests can also show its size and where it is located.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10104528\">",
"      <span class=\"h1\">",
"       How are kidney stones treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment is different for each child. The right treatment depends on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The size, type, and location of the stone",
"       </li>",
"       <li>",
"        How much pain the child has",
"       </li>",
"       <li>",
"        If the child is vomiting, and how much",
"       </li>",
"       <li>",
"        If the child can drink large amounts of fluids",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the stone is small and causes only mild symptoms, the child might be able to stay home and wait for it to pass in the urine on its own. If your child stays home, he or she will probably need to drink a lot of fluids. He or she might also need an over-the-counter medicine for pain, such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;). The doctor might ask you to have your child urinate through a strainer so you can catch the stone when it comes out. The doctor or nurse can tell you how to do this.",
"     </p>",
"     <p>",
"      A child might need treatment in the hospital if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The stone is blocking urine flow",
"       </li>",
"       <li>",
"        The child has severe pain or is vomiting",
"       </li>",
"       <li>",
"        The child cannot drink large amounts of fluid",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Hospital treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain medicine, either in pills or into a vein through an &ldquo;IV&rdquo; if the child is vomiting too much to keep pills down. An IV is a thin tube put into a vein through the skin.",
"       </li>",
"       <li>",
"        Medicine to help pass the stone",
"       </li>",
"       <li>",
"        Fluids given into a vein through an IV",
"       </li>",
"       <li>",
"        Treatment to remove the stone, or break it into smaller pieces so it can pass more easily. Doctors can do this with:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A machine that uses sound waves to break up stones into smaller pieces &ndash; called &ldquo;shock wave lithotripsy.&rdquo;",
"       </li>",
"       <li>",
"        A special kind of surgery that is done through tiny holes in the skin -- During this surgery, the doctor puts tiny tools through the holes and into the child&rsquo;s urinary tract or kidney. Then he or she removes the stone.",
"       </li>",
"       <li>",
"        A thin tube that goes into the body where the urine comes out &ndash; The tube has special tools on the end that doctors can use to break up stones or take them out. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10104543\">",
"      <span class=\"h1\">",
"       Will my child have another kidney stone?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If your child gets a kidney stone, he or she has a higher risk of getting another one later. To help keep this from happening, make sure your child drinks plenty of water.",
"     </p>",
"     <p>",
"      Your doctor or nurse will do tests to find out what caused the first stone. Depending on the results, you might need to change what your child eats. If so, the doctor or nurse can tell you which foods your child should not eat. He or she might also prescribe new medicines to keep your child from having another kidney stone. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10104558\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=see_link\">",
"       Patient information: Kidney stones in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=see_link\">",
"       Patient information: Kidney stones in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"       Patient information: Kidney stones in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/38/27234?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17221 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27234=[""].join("\n");
var outline_f26_38_27234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10104466\">",
"      What are kidney stones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10104481\">",
"      What are the symptoms of kidney stones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10104496\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10104511\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10104528\">",
"      How are kidney stones treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10104543\">",
"      Will my child have another kidney stone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10104558\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17221\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"      Anatomy of the urinary tract in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=related_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=related_link\">",
"      Patient information: Kidney stones in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_38_27235="Effacement and dilatation";
var content_f26_38_27235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58602%7EOBGYN%2F67068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58602%7EOBGYN%2F67068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Effacement and dilatation of the cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cervix is uneffaced and minimally dilated. (B) Cervix is almost completely effaced and dilated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Assessing descent of the fetal head by vaginal examination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fetus is at -2 station signifying that the leading bony edge of the presenting part is two centimeters above the ischial spines. The head is engaged at 0 station.",
"    <div class=\"footnotes\">",
"     Sp: ischial spine.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27235=[""].join("\n");
var outline_f26_38_27235=null;
var title_f26_38_27236="Vespula species";
var content_f26_38_27236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Vespula species",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27236=[""].join("\n");
var outline_f26_38_27236=null;
var title_f26_38_27237="Thiothixene: Pediatric drug information";
var content_f26_38_27237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thiothixene: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"    see \"Thiothixene: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/31/10741?source=see_link\">",
"    see \"Thiothixene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6697664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F227250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Navane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Typical, Phenothiazine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"      see \"Thiothixene: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;12 years: Dose not well established (use not recommended); 0.25 mg/kg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults: Initial: 2 mg 3 times/day, up to 20-30 mg/day; maximum dose: 60 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1 mg, 2 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or water",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of schizophrenia (FDA approved in ages &ge;12 years and adults); also used for management of psychotic disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F227280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thiothixene may be confused with FLUoxetine, thioridazine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Navane&reg; may be confused with Norvasc&reg;, Nubain",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F227278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, nonspecific ECG changes, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, dizziness, drowsiness, extrapyramidal symptoms (akathisia, dystonias, lightheadedness, pseudoparkinsonism, tardive dyskinesia), insomnia restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Discoloration of skin (blue-gray), photosensitivity, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast pain, libido (changes in), changes in menstrual cycle, galactorrhea, gynecomastia, hyper-/hypoglycemia, hyperprolactinemia, lactation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, salivation increased, stomach pain, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficulty in urination, ejaculatory disturbances, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytes, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thiothixene or any component; cross-sensitivity with other phenothiazines may exist; patients with CNS depression, comatose states, circulatory collapse, or blood dyscrasias; avoid use in patients with narrow-angle glaucoma, bone marrow suppression, severe liver or cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease or seizures",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of neuroleptics. May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects. Elevates prolactin levels; use with caution in patients with breast cancer or other prolactin-dependent tumors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is high relative to other neuroleptics, and is dose-dependent; to decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients). Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability; risk may be increased in patients with Parkinson's disease or Lewy body dementia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy. May be sedating, use with caution in disorders in which CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects. Thiothixene has not been evaluated for the treatment of behavioral complications in patients with mental retardation. Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Use is contraindicated in patients with blood dyscrasias.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature; thiothixene is not approved for this indication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause increase in dietary riboflavin requirements",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12585965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic eye exam, CBC with differential, blood pressure, liver enzyme tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elicits antipsychotic activity by postsynaptic blockade of CNS dopamine receptors resulting in inhibition of dopamine-mediated effects; also has alpha-adrenergic blocking activity",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/31/10741?source=see_link\">",
"      see \"Thiothixene: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Wiener JM, &ldquo;Psychopharmacology in Childhood Disorders,&rdquo;",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 1984, 7(4):831-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27237/abstract-text/6151651 /pubmed\" id=\"6151651 \" target=\"_blank\">",
"        6151651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12839 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27237=[""].join("\n");
var outline_f26_38_27237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6697664\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227250\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055688\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055682\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227232\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227217\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055692\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055691\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227280\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227278\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055694\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055681\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055680\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227266\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227226\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055696\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12585965\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055687\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055679\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055686\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=related_link\">",
"      Thiothixene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/31/10741?source=related_link\">",
"      Thiothixene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_38_27238="Causes and clinical manifestations of central adrenal insufficiency in children";
var content_f26_38_27238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and clinical manifestations of central adrenal insufficiency in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27238/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27238/contributors\">",
"     Patricia A Donohoue, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27238/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27238/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27238/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27238/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/38/27238/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is defined by the impaired synthesis and release of adrenocortical hormones. It is classified based upon the mechanism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary adrenal insufficiency results from disease intrinsic to the adrenal cortex.",
"     </li>",
"     <li>",
"      Central adrenal insufficiency can be caused by impaired production or action of adrenocorticotropic hormone (ACTH). It can be caused by several mechanisms: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Secondary adrenal insufficiency results from pituitary disease impairing release of adrenocorticotropic hormone (ACTH). In addition, unresponsiveness of end-organs to adrenocortical hormones is classified as secondary adrenal insufficiency, because this presents in a similar manner as diseases caused by adrenocorticotropic hormone (ACTH) deficiencies.",
"     </li>",
"     <li>",
"      Tertiary adrenal insufficiency results from the impaired release or effect of corticotropin releasing hormone (CRH) from the hypothalamus, which in turn impairs ACTH secretion. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes and clinical manifestations of central adrenal insufficiency in children will be reviewed here. The causes of primary adrenal insufficiency and its manifestations, diagnosis, and treatment in children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=see_link\">",
"     \"Treatment of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of central adrenal insufficiency are caused primarily by glucocorticoid deficiency. These clinical findings include weakness, fatigue, myalgia, arthralgia, and hypoglycemia, and are similar to those seen in primary adrenal insufficiency. A detailed discussion of these manifestations is presented in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, certain findings differ in children with central adrenal insufficiency from those with primary insufficiency. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mineralocorticoid deficiency is not observed, because the renin-angiotensin-aldosterone axis remains intact. As a result, the sodium loss leading to dehydration, hypotension, and hyponatremia, and reciprocal hyperkalemia associated with many forms of primary adrenal insufficiency is not seen. However, patients with central forms of adrenal insufficiency are at risk for isolated and clinically significant dilutional hyponatremia because of loss of the facilitatory role of cortisol on free water excretion. In the latter situation, the patient is not hypovolemic and the serum potassium level is not elevated.",
"     </li>",
"     <li>",
"      Hyperpigmentation is not present in central adrenal insufficiency because ACTH secretion is not increased. By contrast, hyperpigmentation may be seen in primary adrenal insufficiency because of overproduction of proopiomelanocortin (ACTH precursor) and its cleavage products including melanocyte-stimulating hormone (MSH), which results in increased melanin synthesis.",
"     </li>",
"     <li>",
"      There may be clinical manifestations of a pituitary or hypothalamic tumor (such as headache and visual field defects), or symptoms from other anterior pituitary hormone deficiencies.",
"     </li>",
"     <li>",
"      Hypoglycemia is often the presenting symptom, especially in children with adrenal insufficiency resulting from isolated ACTH deficiency. Acute presentations of hypoglycemia can be severe, leading to seizure and coma.",
"     </li>",
"     <li>",
"      Adrenal crisis (hypotension leading to shock) is more likely to occur in primary adrenal insufficiency because of the associated mineralocorticoid deficiency. In central adrenal insufficiency, adrenal crisis is rare, although it occasionally occurs due to glucocorticoid deficiency alone. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SECONDARY ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary adrenal insufficiency is a result of a pituitary gland defect that interferes with the pituitary gland's ability to secrete ACTH (",
"    <a class=\"graphic graphic_table graphicRef56675 \" href=\"UTD.htm?34/51/35643\">",
"     table 1",
"    </a>",
"    ). ACTH deficiency may occur in conjunction with other pituitary hormone deficiencies (hypopituitarism) or may be isolated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypopituitarism",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Congenital causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary adrenal insufficiency because of congenital hypopituitarism results from genetic defects that alter the normal development of the pituitary gland.",
"   </p>",
"   <p>",
"    Mutations in the PROP-1 (Prophet of Pit-1 gene) and Pit-1 genes have been described in patients with multiple pituitary hormone deficiencies. Both genes are necessary for the differentiation of anterior pituitary cells to specific cell types that are precursors to somatotroph, lactotroph, thyrotroph, and gonadotroph cells.",
"   </p>",
"   <p>",
"    Individuals with PROP-1 and POU1F1 (formerly known as Pit-1) defects have variable clinical phenotypes: variable hormonal defects, the order of onset, and severity. As examples, no ACTH deficiency is reported in some case reports, although the deficiency is severe in others. In those with ACTH deficiency, the onset may vary from childhood to late adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes of hypopituitarism\", section on 'Genetic diseases'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\", section on 'Panhypopituitarism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acquired causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired causes of hypopituitarism include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhage &mdash; Trauma may result in hemorrhage in either the pituitary gland or hypothalamus (central adrenal insufficiency), resulting in hypopituitarism. In the premature infant, non-traumatic intracranial hemorrhage also can cause hypopituitarism.",
"     </li>",
"     <li>",
"      Tumor &mdash; Tumors that arise in and around the sella turcica (eg, craniopharyngioma) may result in hypopituitarism. Patients who have had surgery or cranial radiation for brain tumors in the region of the pituitary gland or hypothalamus also are at risk for developing hypopituitarism. The risk from cranial radiation is dependent upon the field and dose of radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"       \"Craniopharyngioma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=see_link&amp;anchor=H25#H25\">",
"       \"Epidemiology, treatment, and prognosis of medulloblastoma\", section on 'Endocrine abnormalities'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Isolated ACTH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated ACTH deficiency as a cause of secondary adrenal insufficiency is rare. In these cases, there is no ACTH secretory response to CRH because of mutations in the biosynthetic pathway of ACTH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proopiomelanocortin mutations &mdash; Proopiomelanocortin (POMC) is a precursor to ACTH. Patients with mutations of the POMC gene present with obesity at an early age, red hair, and secondary adrenal insufficiency.",
"     </li>",
"     <li>",
"      TPIT mutations &mdash; TPIT is a transcription factor required for corticotroph differentiation and POMC production. Patients with mutations of this gene (which are rare) present with hypoglycemia as neonates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed discussion of these genetic disorders is found elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=see_link\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Idiopathic ACTH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports describe patients with isolated ACTH deficiency without disturbance of other pituitary hormonal function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/3\">",
"     3",
"    </a>",
"    ]. The cause is unknown. Patients have normal thyroid function, growth hormone secretion, and usually normal sexual maturation at puberty. Pubertal girls may have absent or scant pubic hair because of the lack of adrenal androgens. Most patients present with hypoglycemia as infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1907216\">",
"    <span class=\"h2\">",
"     End organ unresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unresponsiveness of end-organs to adrenocortical hormones is classified as secondary adrenal insufficiency, because this presents in a similar manner as diseases caused by adrenocorticotropic hormone (ACTH) deficiencies. Causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial glucocorticoid deficiency (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=see_link&amp;anchor=H8#H8\">",
"       \"Unusual causes of adrenal insufficiency\", section on 'Familial glucocorticoid deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudohypoaldosteronism type 1 (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link&amp;anchor=H8#H8\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Pseudohypoaldosteronism type 1'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TERTIARY ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tertiary adrenal insufficiency is caused by impaired hypothalamic function (usually inadequate secretion of corticotropin releasing hormone, CRH) that interferes with the pituitary's ability to secrete ACTH (",
"    <a class=\"graphic graphic_table graphicRef54164 \" href=\"UTD.htm?41/14/42219\">",
"     table 2",
"    </a>",
"    ). As with secondary adrenal insufficiency, tertiary ACTH deficiency may occur in conjunction with other pituitary hormone deficiencies (hypopituitarism) or may be isolated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypopituitarism due to impaired hypothalamic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tertiary adrenal insufficiency results from either congenital or acquired causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Congenital causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital causes include midline brain defects, such as septo-optic dysplasia (de Morsier syndrome, a form of optic nerve hypoplasia), which result in hypothalamic insufficiency and subsequent hypopituitarism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=see_link&amp;anchor=H5#H5\">",
"     \"Congenital anomalies and acquired abnormalities of the optic nerve\", section on 'Hypoplasia'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acquired causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired causes of hypopituitarism based upon a hypothalamic defect include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltrative disorders &mdash; Conditions that destroy the normal hypothalamic tissues by infiltration include iron deposition (which may occur as a consequence of the treatment of hemochromatosis and thalassemia), sarcoidosis, or Langerhans histiocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"       \"Neurologic sarcoidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anorexia nervosa &mdash; In patients with anorexia nervosa, hypothalamic disturbances result in endocrine abnormalities including secondary amenorrhea (decreased gonadotrophin secretion), and hypothyroidism (decreased thyroid stimulating hormone response, TSH). There also are case reports of anorexic patients who have a blunted ACTH response to stress that may lead to episodes of adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/4\">",
"       4",
"      </a>",
"      ]. However, in general patients with anorexia nervosa tend to have elevated serum cortisol concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Injury &mdash; Injury resulting from trauma with intracranial hemorrhage, surgery or radiation can impair hypothalamic function, resulting in hypopituitarism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Isolated ACTH deficiency from suppressed hypothalamic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated ACTH deficiency resulting from suppression of the hypothalamic-pituitary-adrenal axis is the most common cause of adrenal insufficiency. This is principally the result of cessation of long-term, high-dose exogenous glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cessation of glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous glucocorticoid therapy suppresses the normal function and feedback mechanism of the hypothalamic-pituitary-adrenal axis. Withdrawal of glucocorticoids may cause symptoms of adrenal insufficiency because of an inadequate response by the suppressed hypothalamic-pituitary-adrenal axis. This is especially evident during periods of stress (eg, surgery, major trauma, or infection).",
"   </p>",
"   <p>",
"    The following are general guidelines to consider regarding the withdrawal of exogenous glucocorticoid and its effect on the function of the hypothalamic-pituitary-adrenal axis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the administered dose of glucocorticoid is less than the amount needed for physiologic maintenance therapy, then there is no major adrenocortical suppression. There is no need to wean the glucocorticoid dose and no need for exogenous glucocorticoid therapy for stressful events.",
"     </li>",
"     <li>",
"      If the administered dose was greater than physiologic maintenance therapy and the duration of replacement therapy was less than four weeks, there is prompt recovery of the hypothalamic-pituitary-adrenal axis after glucocorticoid withdrawal. As a result, there is no need to wean the glucocorticoid dose and no need for exogenous glucocorticoid therapy for stressful events.",
"     </li>",
"     <li>",
"      If the administered dose was greater than physiologic maintenance therapy and the duration of replacement therapy was greater than four weeks, the hypothalamic-pituitary-adrenal axis may be suppressed. Recovery of adrenal function occurs within six weeks in about half of the patients and within six months for almost all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/5\">",
"       5",
"      </a>",
"      ]. During this time period, exogenous glucocorticoid therapy may be needed for stressful events.",
"     </li>",
"     <li>",
"      Although suppression of the hypothalamic-pituitary-adrenal axial is principally associated with oral or parenteral glucocorticoid therapy, suppression can occasionally occur after the cessation of topical glucocorticoid therapy, contained in nasal spray [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/6\">",
"       6",
"      </a>",
"      ], eye drops [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/7\">",
"       7",
"      </a>",
"      ], inhaled steroids [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/8,9\">",
"       8,9",
"      </a>",
"      ], or dermal creams or lotions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Maternal glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates born to mothers treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    usually have normal adrenal cortisol secretion, because only a small portion of maternal cortisol crosses the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/11\">",
"     11",
"    </a>",
"    ]. As a result, there is normally no suppression of the infant's hypothalamic-pituitary-adrenal axis. &nbsp;",
"   </p>",
"   <p>",
"    However, maternal glucocorticoid therapy that is prolonged and high dose may result in significant placental passage of synthetic glucocorticoids, which could suppress the fetal hypothalamic-pituitary-adrenal axis; this is especially true for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/12\">",
"     12",
"    </a>",
"    ]. It is appropriate to closely monitor these infants for hypoglycemia by obtaining serial serum glucose levels. Neonates may present with feeding difficulties, vomiting, lethargy, jitteriness, and hypoglycemia.",
"   </p>",
"   <p>",
"    Very low birth weight infants who received prenatal synthetic glucocorticoid therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=see_link\">",
"     betamethasone",
"    </a>",
"    ) to prevent respiratory distress syndrome may have transient depression of the hypothalamic-pituitary-adrenal axis. As a result, they may be at risk for hypoglycemia in the first few days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27238/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Infants born at or near term who develop hypoglycemia after antenatal exposure to glucocorticoids can usually be managed with oral supplementation. A few infants with more severe or prolonged hypoglycemia, or those who are not candidates for oral supplementation, may need intravenous glucose infusion or a brief period of glucocorticoid replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Resection of adrenal tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal adenomas and adrenocortical carcinomas that produce cortisol are rare in children. However, they are responsible for 10 to 20 percent of cases of Cushing's syndrome in older children and adolescents. In these patients, high cortisol production is autonomous (independent of ACTH), resulting in suppression of the hypothalamic-pituitary-adrenal axis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link\">",
"     \"Causes and pathophysiology of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After resection of a unilateral cortisol producing tumor, patients are in a situation similar to those who have been weaned from exogenous glucocorticoid therapy. If not administered appropriate replacement glucocorticoid therapy, they are at risk for adrenal insufficiency especially during stressful episodes (eg, surgery, trauma, or infection). Clinical manifestations include fatigue, headache, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is characterized by impaired production of adrenocortical hormones. Primary adrenal insufficiency results from disease intrinsic to the adrenal cortex.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central adrenal insufficiency can be caused by impaired production or action of adrenocorticotropic hormone (ACTH). It can be caused by several mechanisms: (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Secondary adrenal insufficiency results from pituitary disease impairing release of adrenocorticotropic hormone (ACTH). In addition, unresponsiveness of end-organs to adrenocortical hormones is classified as secondary adrenal insufficiency, because this presents in a similar manner as diseases caused by adrenocorticotropic hormone (ACTH) deficiencies (",
"      <a class=\"graphic graphic_table graphicRef56675 \" href=\"UTD.htm?34/51/35643\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tertiary adrenal insufficiency results from the impaired release or effect of corticotropin releasing hormone (CRH) from the hypothalamus (",
"      <a class=\"graphic graphic_table graphicRef54164 \" href=\"UTD.htm?41/14/42219\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signs and symptoms of central adrenal insufficiency are caused primarily by glucocorticoid deficiency. Clinical findings are similar to some of those seen in primary adrenal insufficiency, and include weakness, fatigue, myalgia, arthralgia, and hypoglycemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical features of central adrenal insufficiency differ from those of primary adrenal insufficiency in the following ways: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sodium loss and potassium retention are not present because there is usually no mineralocorticoid deficiency; however, dilutional (isolated) hyponatremia is not uncommon.",
"     </li>",
"     <li>",
"      Hyperpigmentation is not present because ACTH secretion is not increased.",
"     </li>",
"     <li>",
"      There may be clinical manifestations of a pituitary or hypothalamic tumor (such as headache and visual field defects), or symptoms from other anterior pituitary hormone deficiencies.",
"     </li>",
"     <li>",
"      Hypoglycemia is often the presenting symptom and can be severe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In central adrenal insufficiency, ACTH deficiency may be isolated or may occur in conjunction with other pituitary hormone deficiencies (hypopituitarism). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Isolated ACTH deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Hypopituitarism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of central adrenal insufficiency is the cessation of glucocorticoid therapy resulting from the suppression of the hypothalamic-pituitary-adrenal axis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cessation of glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/1\">",
"      Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/2\">",
"      Kanumakala S, Warne GL, Zacharin MR. Evolving hypopituitarism following cranial irradiation. J Paediatr Child Health 2003; 39:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/3\">",
"      CLEVELAND WW, GREEN OC, MIGEON CJ. A case of proved adrenocorticotropin deficiency. J Pediatr 1960; 57:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/4\">",
"      Gold PW, Gwirtsman H, Avgerinos PC, et al. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med 1986; 314:1335.",
"     </a>",
"    </li>",
"    <li>",
"     Donohoue PA. Adrenal disorders. In: Pediatric Practice: Endocrinology, Kappy MS, Allen DB, Geffner ME (Eds), McGraw-Hill Medical, New York 2009. p.168.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/6\">",
"      Norman PS, Winkenwerder WL, Agbayani BF, Migeon CJ. Adrenal function during the use of dexamethasone aerosols in the treatment of ragweed hay fever. J Allergy 1967; 40:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/7\">",
"      Burch PG, Migeon CJ. Systemic absorption of topical steroids. Arch Ophthalmol 1968; 79:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/8\">",
"      Hollman GA, Allen DB. Overt glucocorticoid excess due to inhaled corticosteroid therapy. Pediatrics 1988; 81:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/9\">",
"      Russell G. Inhaled corticosteroids and adrenal insufficiency. Arch Dis Child 2002; 87:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/10\">",
"      Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/11\">",
"      Kenny FM, Preeyasombat C, Migeon CJ. Cortisol production rate. II. Normal infants, children, and adults. Pediatrics 1966; 37:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27238/abstract/12\">",
"      Ballard PL, Gluckman PD, Liggins GC, et al. Steroid and growth hormone levels in premature infants after prenatal betamethasone therapy to prevent respiratory distress syndrome. Pediatr Res 1980; 14:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5815 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27238=[""].join("\n");
var outline_f26_38_27238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SECONDARY ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Congenital causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acquired causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Isolated ACTH deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Idiopathic ACTH deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1907216\">",
"      End organ unresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TERTIARY ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypopituitarism due to impaired hypothalamic function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Congenital causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acquired causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Isolated ACTH deficiency from suppressed hypothalamic function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cessation of glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Maternal glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Resection of adrenal tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/51/35643\" title=\"table 1\">",
"      Causes secondary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/14/42219\" title=\"table 2\">",
"      Causes of tertiary adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=related_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=related_link\">",
"      Craniopharyngioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=related_link\">",
"      Treatment of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=related_link\">",
"      Unusual causes of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_38_27239="Telmisartan: Drug information";
var content_f26_38_27239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Telmisartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/60/13253?source=see_link\">",
"    see \"Telmisartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Micardis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Micardis&reg;;",
"     </li>",
"     <li>",
"      Mylan-Telmisartan;",
"     </li>",
"     <li>",
"      PMS-Telmisartan;",
"     </li>",
"     <li>",
"      Sandoz-Telmisartan;",
"     </li>",
"     <li>",
"      Teva-Telmisartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 40 mg once daily; usual maintenance dose range: 20-80 mg/day. Patients with volume depletion should be initiated on the lower dosage with close supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cardiovascular risk reduction:",
"     </b>",
"     Oral: Initial: 80 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     It is unknown whether doses &lt;80 mg/day are associated with a reduction in risk of cardiovascular morbidity or mortality.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F224978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 20 mg/day; usual maintenance dose range: 20-80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cardiovascular risk reduction:",
"     </b>",
"     Oral: Initial 80 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4433272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required; hemodialysis patients are more susceptible to orthostatic hypotension",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F224979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate therapy with low dose; titrate slowly and monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling: Recommended initial dose: 40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micardis&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micardis&reg;: 40 mg, 80 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9614174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (may be used alone or in combination with other antihypertensive agents); cardiovascular risk reduction in patients &ge;55 years of age unable to take ACE inhibitors and who are at high risk of major cardiovascular events (eg, MI, stroke, death)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be associated with worsening of renal function in patients dependent on renin-angiotensin-aldosterone system.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Intermittent claudication (7%; placebo 6%), chest pain (&ge;1%), hypertension (&ge;1%), peripheral edema (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (&ge;1%), fatigue (&ge;1%), headache (&ge;1%), pain (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin ulcer (3%; placebo 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3%), abdominal pain (&ge;1%), dyspepsia (&ge;1%), nausea (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%), myalgia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (7%), sinusitis (3%), cough (&ge;1%), pharyngitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal ECG, abscess, allergic reaction, anaphylaxis, anemia, angina, angioedema, arthritis, asthma, atrial fibrillation, bradycardia, cerebrovascular disorder, CHF, conjunctivitis, creatinine kinase increased, depression, diabetes mellitus, eczema, edema, epistaxis, erectile dysfunction, fixed drug eruption, fungal infection, gastroenteritis, gout, hepatic dysfunction, hypercholesterolemia, hyperkalemia, hypersensitivity, hypoglycemia (diabetic patients), hypotension, impotence, insomnia, MI, migraine, neoplasm, orthostatic hypotension (more frequent in dialysis patients), otitis media, renal failure, rhabdomyolysis, reflux, serum creatinine increased, syncope, tachycardia, tendon pain, thrombocytopenia, uric acid increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to telmisartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications: Second and third trimesters of pregnancy; breast-feeding; fructose intolerance",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with telmisartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients who have biliary obstructive disorders or hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use telmisartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction; concurrent use with ramipril is not recommended. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: Product contains sorbitol. The Canadian labeling (not in U.S. labeling) contraindicates use in fructose intolerant patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F224999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Telmisartan may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramipril: Telmisartan may increase the serum concentration of Ramipril. Concentrations of the active metabolite, ramiprilat, may also be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F224969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Some herbal medications may have hypertensive or hypotensive properties; others may increase or decrease the antihypertensive effect of telmisartan. Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F224982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F224960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Product contains sorbitol.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F224958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Micardis Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $160.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $160.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $160.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F224949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; electrolytes, serum creatinine, BUN",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kinzalmono (AT, BE, CH, CZ, DE, DK, EE, FI, FR, GB, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Micardis (AE, AR, AT, AU, BE, BF, BH, BJ, BR, CH, CI, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, ID, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, OM, PA, PH, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Predxal (MX);",
"     </li>",
"     <li>",
"      Pritor (AR, KP, PE, PH, VE);",
"     </li>",
"     <li>",
"      Pritoral (CN);",
"     </li>",
"     <li>",
"      Saitan (CL);",
"     </li>",
"     <li>",
"      Telma-20 (IN);",
"     </li>",
"     <li>",
"      TEZEO (BG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium as well as water are reabsorbed. The end result is an elevation in blood pressure. Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. This binding prevents angiotensin II from binding to the receptor thereby blocking the vasoconstriction and the aldosterone secreting effects of angiotensin II.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Orally active, not a prodrug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 500 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99.5%; primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via conjugation to inactive metabolites; not metabolized via CYP",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability (dose dependent): 42% to 58%; Hepatic impairment: Approaches 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (97%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Total body: 800 mL/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K, Kjekshus J, et al, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karlberg BE, Lins LE, and Hermansson K, &ldquo;Efficacy and Safety of Telmisartan, a Selective AT1 Receptor Antagonist, Compared With Enalapril in Elderly Patients With Primary Hypertension. TEES Study Group,&rdquo;",
"      <i>",
"       J Hypertens",
"      </i>",
"      , 1999, 17(2):293-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/10067800/pubmed\" id=\"10067800\" target=\"_blank\">",
"        10067800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators, &ldquo;Effects of the Angiotensin-Receptor Blocker Telmisartan on Cardiovascular Events in High-risk Patients Intolerant to Angiotensin-Converting Enzyme Inhibitors: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 372(9644):1174-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/38/27239/abstract-text/18757085/pubmed\" id=\"18757085\" target=\"_blank\">",
"        18757085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10275 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27239=[""].join("\n");
var outline_f26_38_27239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709066\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224973\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224974\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225005\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224977\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224978\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4433272\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224979\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224951\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224937\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9614174\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224952\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225003\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224956\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224941\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224999\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224946\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224969\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224947\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224959\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224982\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224960\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224958\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224949\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224961\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224940\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224955\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/60/13253?source=related_link\">",
"      Telmisartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_38_27240="Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations";
var content_f26_38_27240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27240/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/38/27240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of atherosclerotic coronary artery disease (CAD) has evolved significantly due in part to advances in revascularization with both percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG).",
"   </p>",
"   <p>",
"    Among patients with stable angina, the goals of medical therapy, PCI, and CABG are to delay or prevent the complications of coronary disease in an effort to prolong life, decrease cardiac morbidity, and alleviate symptoms. Patient age, left ventricular function, and the severity of atherosclerosis and symptoms frequently affect the outcome and can influence the choice of a particular management strategy.",
"   </p>",
"   <p>",
"    The recommended approach to choosing between bypass surgery and PCI in patients with stable angina pectoris who are candidates for intervention will be reviewed here. The major clinical studies that provide the evidence to support the recommendations made in this topic are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to revascularization in patients with left main disease, acute coronary syndromes, or diabetes is discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link\">",
"     \"Management of left main coronary artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of which method of revascularization is used, aggressive risk-factor modification is necessarily in all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with revascularization, as opposed to continuing medical therapy, is made in three groups of stable patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with activity-limiting symptoms despite maximum medical therapy",
"     </li>",
"     <li>",
"      Active patients who want PCI for improved quality of life compared to medical therapy, such as those who are not tolerating medical therapy well, or who want to increase their activity level.",
"     </li>",
"     <li>",
"      Patients with anatomy for which revascularization has a proven survival benefit such as significant left main coronary artery disease (greater than 50 percent luminal narrowing) or multivessel coronary artery disease (CAD) with a reduction left ventricular ejection fraction and a large area of potentially ischemic myocardium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CABG VERSUS PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of CABG versus PCI is dependent upon a number of factors, including the location and number of vessels involved, and the anatomic complexity of the lesions requiring revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCI with drug-eluting stents is preferred in patients with one or two vessel disease (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H2#H2\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'PCI versus CABG for single vessel disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CABG is preferred when there is a large amount of myocardium at risk, as with unprotected (no patent distal bypass grafts) left main coronary disease (",
"      <a class=\"graphic graphic_movie graphicRef70747 \" href=\"UTD.htm?3/55/3967\">",
"       movie 1",
"      </a>",
"      ) and diffuse three-vessel coronary disease (",
"      <a class=\"graphic graphic_movie graphicRef79485 \" href=\"UTD.htm?9/44/9934\">",
"       movie 2",
"      </a>",
"      ), particularly in patients with diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H32#H32\">",
"       \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Newer evidence suggests some patients with left main coronary artery disease who were previously referred for CABG may be equally well treated with PCI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link\">",
"       \"Management of left main coronary artery disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H19\">",
"       'Summary and recommendations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients in whom complete revascularization cannot be accomplished by PCI are candidates for CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, any experienced centers perform CABG only in patients in whom PCI is technically not feasible, such as those with total chronic occlusions or extensive and severe diffuse lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Balloon angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of large randomized trials published in the mid-1990s directly compared CABG with balloon angioplasty. Summarized briefly, the major finding in these trials was that survival is similar with CABG and balloon angioplasty, but that repeat intervention is much more common with balloon angioplasty (",
"    <a class=\"graphic graphic_figure graphicRef77158 \" href=\"UTD.htm?30/50/31534\">",
"     figure 1",
"    </a>",
"    ). Although the follow-up in the trials was less than five years, a prolonged follow-up of almost 2000 patients in an observational series showed similar results at 10 and 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trials with bare-metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial trials with PTCA are not directly relevant to current practice because of the lack of use of stents or, in most cases, of internal mammary artery rather than saphenous vein grafts during CABG (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"UTD.htm?23/28/24013\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These concerns were overcome in ARTS I and SoS, two randomized trials that compared CABG, mostly with arterial grafts, to PCI with bare-metal stent implantation in patients with multivessel disease. The two approaches produced similar outcomes except for a higher rate of target vessel revascularization with PCI (17 versus 4 percent and 21 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The rate of restenosis with stenting was lower than that seen in BARI with angioplasty alone (about 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H11#H11\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'Stenting versus CABG for multivessel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the findings of ARTS I and SoS are not relevant to current practice because of the availability of drug-eluting stents which, compared to bare metal stents, reduce the rate of both angiographic restenosis and repeat target vessel revascularization by about 70 percent (",
"    <a class=\"graphic graphic_figure graphicRef53472 \" href=\"UTD.htm?35/25/36254\">",
"     figure 3",
"    </a>",
"    ), largely removing one of the major limitations to PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drug-eluting stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI with DES is currently the procedure of choice in the majority of patients, since the revascularization rate during long-term follow-up is lower than with balloon angioplasty or stenting with bare-metal stents. The efficacy of PCI with DES compared to CABG was best evaluated in the SYNTAX trial of patients with left main and three vessel CAD. Observational data are also available from the ARTS II and New York State registries. In all three studies, the revascularization rate at 12 months (and longer) with DES was significantly higher than with CABG.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H16#H16\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'Drug-eluting stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the SYNTAX trial, which used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting TAXUS stents, overall results showed superiority for MACE of CABG for three vessel CAD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\"",
"    </a>",
"    .) Subgroup analyses based on the SYNTAX score (see",
"    <a class=\"local\" href=\"#H468900345\">",
"     'SYNTAX score and SYNTAX score II'",
"    </a>",
"    below), a measure of lesion and disease complexity, showed the benefit of CABG was greatest among patients with intermediate (22 to 32) or complex (SYNTAX score &ge;33) disease. During longer-term follow-up (three and five years), CABG was associated with a mortality benefit in the complex SYNTAX score subgroup. The difference in the lowest SYNTAX score subgroup (&le;22), however, was not significant and was related to a higher risk for repeat procedures for DES. Of note, more patients in the CABG group withdrew consent or were lost to follow-up, which should be considered in the overall interpretation of data. Other observational data also suggest that disease complexity is an important effect modifier, with similar outcomes for CABG and PCI in those with low-complex disease, and superiority for CABG in patients with more-complex disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H468900345\">",
"    <span class=\"h3\">",
"     SYNTAX score and SYNTAX score II",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom it is not clear whether PCI or CABG should be preferred, we believe it is reasonable to use the SYNTAX score to help guide decision making [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/11\">",
"     11",
"    </a>",
"    ]. However, no studies have shown that patients managed using the score do better than those who are not.",
"   </p>",
"   <p>",
"    The SYNTAX score is a semi-quantitative tool is based on the results of coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. It was developed during the SYNTAX trial, to classify patients according to the severity of their coronary artery disease (CAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The score incorporates characteristics of lesion complexity, lesion location, and the number of lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link&amp;anchor=H266319236#H266319236\">",
"     \"Management of left main coronary artery disease\", section on 'SYNTAX trial subgroup analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the criticisms of the SYNTAX score has been that it does not include any clinical variables. In an attempt to improve the predictive capability of the SYNTAX score, the SYNTAX score II was developed using baseline patient data in the SYNTAX trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/15\">",
"     15",
"    </a>",
"    ]. It contains eight predicators: the anatomical SYNTAX score, age, creatinine clearance, left ventricular ejection fraction, presence of unprotected left main coronary artery disease, peripheral artery disease, female sex, and chronic obstructive pulmonary disease. The SYNTAX score II was externally validated using a large all comers (DELTA) registry of patients with three-vessel or complex CAD. The SYNTAX score II was better able to predict long-term mortality in patients with complex CAD than the angiographic SYNTAX score. While promising, further validation of this new score is needed before we recommend its use.",
"   </p>",
"   <p>",
"    Since the overall findings of the SYNTAX trial favor CABG, the finding of comparable outcomes in the subgroup with a low SYNTAX score must be interpreted with caution. We are not confident that we know the optimal strategy in such patients. We suggest CABG for many of these patients, but some of our authors and reviewers frequently perform PCI, after discussing the pros and cons of both approaches with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Potential concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the increase in revascularization, there are other potential concerns with multivessel or complex lesion stenting with drug-eluting stents compared to CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In diffuse lesions requiring multiple overlapping stents, there has been concern about an increase in inflammation and ischemic complications. Such an increase in risk was suggested in the TAXUS V trial of patients with complex coronary artery disease in which the 30-day rate of myocardial infarction, mostly periprocedural and non-Q wave, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stents was significantly higher than with bare metal stents (8.3 versus 3.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/17\">",
"       17",
"      </a>",
"      ]. The paclitaxel stents still had the expected significant reduction in target lesion revascularization (12.6 versus 28.2 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"       \"Use of intracoronary stents for specific coronary lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A high risk of subacute and late stent thrombosis (5 of 17 [29 percent] in one series) in patients who prematurely discontinue antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A more pronounced increase in revascularization rate compared to CABG in diabetic patients (12.6 versus 4.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"       \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A greater likelihood that of requiring revascularization at other sites due to progressive coronary artery disease. In a review of 3747 patients undergoing culprit lesion PCI from the National Heart, Lung, and Blood Institute Dynamic Registry, 216 (5.8 percent) required nontarget lesion PCI at one year: 87 percent of these nontarget lesions were &le;60 percent stenosis at initial PCI (mean 42 percent compared to 84 percent during the recurrent event) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Registry data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple large observational studies have compared CABG to DES in patients with multivessel CAD. The results are conflicting and the studies are flawed; we do not feel the results of these should significantly influence decisions regarding the choice of revascularization in current practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H16727687#H16727687\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'Evidence from registries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24404075\">",
"    <span class=\"h2\">",
"     Risk of stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both CABG and PCI are associated with a small but important risk of stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=see_link&amp;anchor=H3#H3\">",
"     \"Neurologic complications of cardiac surgery\", section on 'Stroke'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H30#H30\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most of the randomized trials comparing CABG to PCI, with the exception of the SYNTAX trial, no significant difference has been found in the risk of stroke. However, each trial was insufficiently powered to detect a significant difference. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of 19 trials (comparing CABG to PCI) with nearly 11,000 patients found a significantly higher rate of stroke with CABG at 30 days and at a median follow-up of 12.1 months (1.20 versus 0.34 percent; odds ratio [OR] 2.94, 95% CI 1.69-5.09 and 1.83 versus 0.99 percent; OR 1.67, 95% CI 1.09-2.56) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/21\">",
"     21",
"    </a>",
"    ]. Limitations to this study included differing definitions of stroke across studies and the inability to examine the relationship between stroke and subsequent mortality. Similar results were found in a separate analysis of 27 observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patients in whom PCI might be preferred",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI, rather than CABG, is a reasonable approach in the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal left anterior descending coronary artery disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=see_link\">",
"       \"Management of significant proximal left anterior descending coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PCI, in preference to CABG, may be considered in the following patient groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two vessel disease, particularly if the left anterior coronary artery is not involved.",
"     </li>",
"     <li>",
"      Older patients or those with significant comorbidity who may have prohibitively high operative risks or short life expectancies.",
"     </li>",
"     <li>",
"      In patients who refuse surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with low complexity multivessel disease who do not have diabetes. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Drug-eluting stents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patients with left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy for patients with multivessel coronary disease with left ventricular dysfunction remains controversial and was not formally addressed in the large randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/22\">",
"     22",
"    </a>",
"    ]. Evidence upon which recommendations for one type of revascularization or another for these patients can be made comes from older studies of CABG versus medical therapy in which CABG led to better outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H13#H13\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'COURAGE and FAME II trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to proceed with either CABG or PCI in these patients may be affected by a number of variables including patient and physician preference, the severity of left ventricular dysfunction, the severity and extent of CAD, the potential for completeness of revascularization, and the expertise of the surgeon performing the bypass and of the cardiologist performing the percutaneous intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patients with previous CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data evaluating PCI versus repeat CABG in patients with prior CABG are limited.",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task forces have published guidelines for choosing the optimal procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=see_link&amp;anchor=H4#H4\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the coronary anatomy is equally well suited for both PCI and bypass surgery, the decision should be made jointly by the patient, referring physician, cardiologist, and cardiothoracic surgeon. Attention must be paid to the patient's expectations and willingness to undergo repeat procedures, if necessary. Some patients remain fearful of open heart surgery with increased periprocedural morbidity and mortality and the ensuing 4 to 12 week convalescence, while others are unwilling to undergo repeat interventions, although the rate is markedly reduced with drug-eluting stents. Other patients are strongly stroke averse and are willing to accept an increased risk of revascularization after PCI, in order to decrease the risk of stroke. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Drug-eluting stents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The importance of clinical decision making after consideration of all of these factors should not be underestimated and cannot be easily replaced even by the best evidence from observational or randomized clinical trials.",
"   </p>",
"   <p>",
"    Multivessel PCI should",
"    <strong>",
"     not",
"    </strong>",
"    be undertaken by low volume operators who have limited experience with complex coronary lesions. Furthermore, in high-risk situations, multivessel PCI may require two revascularization procedures performed at separate times (staged revascularization). Thus, the patient must be willing to return to the catheterization laboratory on several occasions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations regarding the choice between CABG and PCI in the 2011 PCI guideline from American College of Cardiology Foundation",
"    <span class=\"nowrap\">",
"     (ACCF)/",
"    </span>",
"    American Heart Association",
"    <span class=\"nowrap\">",
"     (AHA)/Society",
"    </span>",
"    for Cardiovascular Angiography and Interventions (SCAI) PCI and the 2011 CABG guideline from the",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    are consistent with each other and generally consistent with our recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines on myocardial revascularization were published by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27240/abstract/5\">",
"     5",
"    </a>",
"    ]. The following summarizes recommendations for the choice between CABG and PCI in patients with stable angina who have lesions suitable for both procedures and a low predicted surgical mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCI is favored to CABG in patients with one or two vessel disease not involving the proximal left anterior descending coronary artery (LAD).",
"     </li>",
"     <li>",
"      CABG is favored to PCI in patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With one or two vessel and proximal LAD disease;",
"     </li>",
"     <li>",
"      With three vessel disease and SYNTAX score &gt;22; in patients with lower SYNTAX scores, PCI is considered a reasonable alternative;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recognizing the diversity of clinical and anatomic scenarios in patients with stable disease, this document emphasizes the importance of considering the specific scenario, as well as patients&rsquo; preferences, in the process of decision making.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guideline recommendations for patients with left main coronary artery disease are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link&amp;anchor=H266319516#H266319516\">",
"     \"Management of left main coronary artery disease\", section on 'Major society guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"       \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with stable angina, the goals of medical therapy or revascularization are to prolong life, decrease cardiac morbidity, and alleviate symptoms.",
"     </li>",
"     <li>",
"      Revascularization with either coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) is indicated the following groups of patients with stable angina pectoris:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with activity-limiting symptoms despite optimal medical therapy",
"     </li>",
"     <li>",
"      Active patients who prefer PCI for improved quality of life compared to medical therapy",
"     </li>",
"     <li>",
"      Those with anatomy for which revascularization has a proven survival benefit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for revascularization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with left main or three vessel coronary artery disease, the combined outcome of death, myocardial infarction (MI), and stroke appears similar in the first year in such patients managed with either CABG or PCI. However, revascularization rates are higher with PCI. At longer-term follow-up, survival and freedom from MI may be greater in patients managed with CABG. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'CABG versus PCI'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Available data suggest that most patients with one or two vessel disease are best managed with PCI, while those with multivessel or left main disease associated with impaired left ventricular systolic function are best managed with CABG.",
"      <br/>",
"      <br/>",
"      For patients who fall into neither of these categories, it is uncertain which procedure is preferable. We suggest that patients be informed in detail about the strengths and weaknesses of each procedure, including information about local expertise; shared decision making is extremely important in these patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Special circumstances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our recommendations for patients with stable angina pectoris assume that local expertise is satisfactory for both PCI and CABG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend CABG, as opposed to PCI, in patients with three vessel coronary artery disease and an LVEF &lt;30 percent or in those with intermediate to high complex coronary anatomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Drug-eluting stents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'CABG versus PCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest CABG, as opposed to PCI, for patients with three-vessel coronary artery disease, relatively well preserved left ventricular systolic function, and low complexity coronary anatomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This last recommendation assumes a preference by patients for a lower likelihood of having to return for repeat revascularization. For those patients who are less concerned about the possibility of repeat revascularization, PCI is a reasonable option.",
"     </li>",
"     <li>",
"      The anatomic complexity of the lesions may influence the relative benefit of CABG and PCI. For patients with intermediate anatomic complexity, we advise seeking the input of a cardiothoracic surgeon prior to proceeding directly to PCI at the time of diagnostic coronary angiography. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Drug-eluting stents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to revascularization in appropriately selected patients, optimal treatment of patients with CAD should also focus on risk-factor reduction. This includes low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , reaching treatment goals for hypertension and serum lipids, avoidance of smoking, controlling the serum glucose in patients with diabetes, and referral to a cardiac rehabilitation program. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=see_link\">",
"       \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8495562\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. David O. Williams for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/2\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/3\">",
"      Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/4\">",
"      Silber S, Albertsson P, Avil&eacute;s FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/5\">",
"      Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/6\">",
"      Bell MR, Gersh BJ, Schaff HV, et al. Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery Surgery Study (CASS) Registry. Circulation 1992; 86:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/7\">",
"      van Domburg RT, Foley DP, Breeman A, et al. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome. Eur Heart J 2002; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/8\">",
"      Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/9\">",
"      SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002; 360:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/10\">",
"      Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335:217.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.syntaxscore.com/ (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/12\">",
"      Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010; 121:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/13\">",
"      Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1:219.",
"     </a>",
"    </li>",
"    <li>",
"     file://syntaxscore.com/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/15\">",
"      Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013; 381:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/16\">",
"      Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 2006; 47:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/17\">",
"      Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/18\">",
"      Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/19\">",
"      Macaya, C, Garcia, H, Serruys, P, et al. Sirolimus-eluting stents versus surgery and bare metal stenting in the treatment of diabetic patients with multivessel disease&mdash;a comparison between ARTS I and ARTS II (abstract). Circulation 2005; 112:II-655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/20\">",
"      Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005; 111:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/21\">",
"      Palmerini T, Biondi-Zoccai G, Reggiani LB, et al. Risk of stroke with coronary artery bypass graft surgery compared with percutaneous coronary intervention. J Am Coll Cardiol 2012; 60:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/22\">",
"      Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/23\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/24\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27240/abstract/25\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1579 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-743D36F484-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27240=[""].join("\n");
var outline_f26_38_27240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CABG VERSUS PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Balloon angioplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trials with bare-metal stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drug-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H468900345\">",
"      - SYNTAX score and SYNTAX score II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Potential concerns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Registry data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24404075\">",
"      Risk of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patients in whom PCI might be preferred",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patients with left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patients with previous CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8495562\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1579\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1579|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/50/31534\" title=\"figure 1\">",
"      Revascularization PTCA v CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24013\" title=\"figure 2\">",
"      IMA versus vein graft patency after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/25/36254\" title=\"figure 3\">",
"      Lack of restenosis with sirolimus stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1579|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?3/55/3967\" title=\"movie 1\">",
"      Left main coronary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?9/44/9934\" title=\"movie 2\">",
"      Triple vessel coronary disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=related_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=related_link\">",
"      Late recurrent angina pectoris after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=related_link\">",
"      Management of significant proximal left anterior descending coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_38_27241="Approach to chest pain in children";
var content_f26_38_27241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to chest pain in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Robert L Geggel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27241/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27241/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/38/27241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain is a common presenting complaint in children. Although the etiology is benign in most cases, this symptom may lead to school absences and restriction of activities and causes considerable anxiety in patients and their families. A thorough history and physical examination usually can determine the cause and identify patients who require acute intervention and those who can be managed with reassurance and continued follow-up. Laboratory testing is necessary only in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/1\">",
"     1",
"    </a>",
"    ]. In the absence of associated symptoms of illness, positive findings on physical examination related to the cardiac or respiratory systems, or symptoms during exertion, a serious organic cause is unlikely.",
"   </p>",
"   <p>",
"    The emergent evaluation of respiratory distress in children and adolescents, with or without chest pain, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain is a common symptom in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In an urban black adolescent population, for example, this symptom was the seventh most common reason for seeing a physician [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/4\">",
"     4",
"    </a>",
"    ]. Children younger than 12 years old also are affected, accounting for approximately one-half of patients with this symptom who presented to an emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/1\">",
"     1",
"    </a>",
"    ]. There is no gender predilection. An equal number of males and females present with chest pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain can be acute or chronic. Estimates of the relative proportions depend upon the setting in which patients are evaluated. In a report of 407 children with chest pain seen in an emergency department, symptoms were acute (less than 48 hours duration) in 43 percent and chronic (more than six months duration) in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, in a study of 100 adolescents with chest pain seen in a general pediatric clinic, pain was present longer than six months in 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5\">",
"     5",
"    </a>",
"    ]. Some patients with idiopathic chest pain report symptoms for longer than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/1,5-8\">",
"     1,5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest pain has important functional consequences because it may result in restriction of activities and school absences. In the review of 100 adolescents noted above, restriction of activities was reported in 69 percent and 41 percent had absences from school because of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest pain causes considerable anxiety in patients and their families. Because of its association with fatal heart disease in adults, this symptom often is viewed as a harbinger of serious cardiac disease (",
"    <a class=\"graphic graphic_table graphicRef63645 \" href=\"UTD.htm?11/6/11371\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5,6,9\">",
"     5,6,9",
"    </a>",
"    ]. This interpretation is more common after the occurrence of sudden death involving an athlete in the community or at the professional level.",
"   </p>",
"   <p>",
"    Adolescents with chest pain often are worried about their symptoms. In the series of adolescent patients seen in a general pediatric clinic, nearly all of whom had no serious illness, 44 percent thought they were having a heart attack or were worried about heart disease (12 percent) or cancer (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of chest pain in children vary among reports and depend in part upon whether patients were seen in an emergency department with acute symptoms or in a pediatric or cardiology setting with a more chronic complaint (",
"    <a class=\"graphic graphic_table graphicRef76014 \" href=\"UTD.htm?5/60/6092\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/1,2,5,6,8-14\">",
"     1,2,5,6,8-14",
"    </a>",
"    ]. In both settings, patients typically have no serious underlying organic medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/6-8,15\">",
"     6-8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to perceptions of the patient and family, cardiac disease is uncommon (1 to 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/16\">",
"     16",
"    </a>",
"    ]. A diagnosis cannot be established in a substantial proportion of cases (21 to 45 percent); these are considered idiopathic. Similar to most patients with chest pain, those with idiopathic pain typically have no serious underlying medical condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Musculoskeletal conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions affecting the musculoskeletal system are identified as the cause of chest pain in 15 to 31 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. These comprise the largest category of known etiologies.",
"   </p>",
"   <p>",
"    Musculoskeletal pain can be traumatic or nontraumatic, although the latter is more common. Trauma may result in a rib fracture, bruise, or, rarely, hemopericardium. Nontraumatic conditions include costochondritis, myalgia, and slipping rib syndrome, and are known collectively as the chest wall syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Costochondritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costochondritis is a frequent cause of chest pain. In one report, tenderness of the costal cartilages was the only abnormal finding in 79 of 100 adolescents who complained of chest and upper abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/3\">",
"     3",
"    </a>",
"    ]. Costochondritis typically was unilateral, occurring more frequently on the left side. The left fourth sternocostal cartilage was affected most often. One type of injury producing strain of chest wall muscles and ligaments is lifting a heavy school bag and carrying it over one shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Slipping rib syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slipping rib syndrome involves the eighth, ninth, and tenth ribs, which are not attached by costal cartilage to the sternum but are attached to each other by fibrous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. If these fibrous connections are weakened or ruptured by trauma, the ribs can slip and impinge on the intercostal nerve, producing pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Precordial catch",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon and benign etiology of musculoskeletal chest pain in children is precordial catch, also known as Texidor's twinge [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/10,13,14,22,23\">",
"     10,13,14,22,23",
"    </a>",
"    ]. This condition consists of brief episodes (seconds to a few minutes) of sharp pain that can be localized with the fingertip to one interspace at the left sternal border or cardiac apex. The pain has a sudden onset, typically at rest or during mild activity, and increases with inspiration. The cause is unknown, although it has been associated with poor posture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychogenic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain may have a psychogenic etiology in as many as 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5,9,11\">",
"     5,9,11",
"    </a>",
"    ]. This cause is more common in children older than 12 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The pain may reflect anxiety or a conversion disorder triggered by stressful events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/11,24,25\">",
"     11,24,25",
"    </a>",
"    ]. In one series, approximately one-third of children with chest pain seen in a general pediatric clinic had a history of stressful events, including recent death, illness or accident in the family, family separations, or school changes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5\">",
"     5",
"    </a>",
"    ]. Most children with psychogenic chest pain have other recurrent somatic complaints, including headache or abdominal or extremity pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Approximately one-third have significant sleep disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperventilation can result in chest pain that frequently is accompanied by lightheadedness or paresthesias. The mechanism is uncertain. Possibilities include spasm of the diaphragm resulting from rapid, repetitive use, gastric distension arising from aerophagia, or coronary artery vasoconstriction caused by hypocapneic alkalosis (the latter tested in adults with ischemic coronary disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Breast causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast can be a source of chest pain in adolescent patients, although it typically accounts for less than 5 percent of complaints. Pain may be a presenting symptom in males with gynecomastia. These patients also may have anxiety about the size of their breasts. Painful conditions of the breast in females include mastitis, fibrocystic disease, thelarche, or tenderness associated with pregnancy. Worries about cancer are often present in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Respiratory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory disorders, including pneumonia, bronchitis, and reactive airway disease, are common causes of acute chest pain. Exercise-induced bronchoconstriction appears to be a frequent cause of chest discomfort even in patients without audible wheezing. This was illustrated by a study of pulmonary function testing before and after exercise in 88 otherwise healthy children and adolescents with chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/29\">",
"     29",
"    </a>",
"    ]. Exercise decreased forced expiratory volume in one second or peak expiratory flow rate in 72.7 percent of the children. Subjective or objective improvement occurred in 97 and 70 percent, respectively, of 36 children given inhaled",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    . In this condition, air hunger typically precedes the chest pain.",
"   </p>",
"   <p>",
"    Less common causes are pleuritis, pleural effusion, pneumothorax, and pneumomediastinum. Air leak (pneumothorax or pneumomediastinum) occasionally is a complication of trauma or an underlying disorder, such as reactive airway disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/33\">",
"     33",
"    </a>",
"    ], or Marfan syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/34\">",
"     34",
"    </a>",
"    ], but is often idiopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/14\">",
"     14",
"    </a>",
"    ]. Other respiratory causes of chronic pain in cystic fibrosis are pleuritis and rib fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal disorders that cause chest pain can affect the esophagus (the most common site), stomach, bowel, biliary tract, and pancreas. In one series, among 21 children with a gastrointestinal cause of chest pain, 16 had esophagitis (typically caused by gastroesophageal reflux), four had gastritis, and one had diffuse esophageal spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal endoscopy and manometry may detect abnormalities in children with chest pain, even without other gastrointestinal symptoms. This was demonstrated in a study of 83 children with chest pain who underwent these procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/37\">",
"     37",
"    </a>",
"    ]. Esophageal histology and motility were normal in 47 patients (57 percent). Among the others, 15 (18 percent) had esophagitis with normal motility, 13 (16 percent) had normal histology and dysmotility, and 8 (9 percent) had both esophagitis and dysmotility. The most common motility disorders were diffuse esophageal spasm and achalasia, which occurred in seven and four patients, respectively.",
"   </p>",
"   <p>",
"    In addition to those mentioned above, esophageal disorders causing chest pain include strictures, foreign body, and caustic ingestions. Conditions affecting the stomach and bowel include ulcer and irritable bowel. Cholecystitis may cause symptoms that suggest angina in adults, but is uncommon in children. Biliary (eg, gallstones) and pancreatic disorders are rare causes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of chest pain related to the pulmonary vascular system include pulmonary embolism and pulmonary hypertension. Children with sickle cell disease may develop acute chest syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Acute chest syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolism is unusual in children but can present with chest pain. In a retrospective study in which 18 affected patients were identified over a 15-year period, the incidence of pulmonary embolism was estimated as 78 per 100,000 hospitalized adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/39\">",
"     39",
"    </a>",
"    ]. In this series, major risk factors were oral contraceptive use and pregnancy termination (75 percent of females) and trauma (67 percent of males). Other predisposing causes include immobility, ventriculoatrial shunts for hydrocephalus, central venous catheters, solid tumors, heart disease, infection, dehydration, hypercoagulable states, low cardiac output, or obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension can be secondary to lung disease, congenital heart disease, or other systemic disorders, or have no identified cause (idiopathic pulmonary arterial hypertension) (",
"    <a class=\"graphic graphic_table graphicRef57644 \" href=\"UTD.htm?28/4/28748\">",
"     table 3",
"    </a>",
"    ). It may rarely cause chest pain but more often causes other symptoms, such as fatigue, lethargy, and dyspnea or syncope with exertion. The mechanism of chest pain is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Acute chest syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute chest syndrome is a serious and potentially fatal cause of chest pain in patients with sickle cell disease. It occurs in almost one-half of patients with the disorder. In addition to chest pain, acute chest syndrome is characterized by the presence of a new pulmonary infiltrate involving at least one complete lung segment (not atelectasis), temperature &gt;38.5&ordm;C, and tachypnea, wheezing, or cough [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link\">",
"     \"Pulmonary complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiac conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac conditions are a rare but potentially serious cause of chest pain in children. Cardiac disease is more likely if chest pain occurs during exertion and is recurrent. Most conditions will be associated with an abnormal cardiac examination or coexisting symptoms. In patients with known heart disease, chest pain may indicate progression of the underlying condition. Conditions that may present with chest pain include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe left ventricular outflow tract obstruction caused by aortic stenosis (subvalvar, valvar, or supravalvar), obstructive cardiomyopathy, or coarctation of the aorta may cause decreased coronary blood flow and angina [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aortic root dissection associated with Marfan syndrome, Turner syndrome, type IV Ehlers-Danlos syndrome, chronic systemic hypertension, homocystinuria, rare familial aortopathies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/45\">",
"       45",
"      </a>",
"      ], or cystic medial necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/41\">",
"       41",
"      </a>",
"      ]. (See appropriate topics).",
"     </li>",
"     <li>",
"      Pericarditis, which often is idiopathic, may also be caused by an infectious agent or associated with an underlying condition such as collagen vascular disorder, uremia, neoplasm, or trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/46\">",
"       46",
"      </a>",
"      ]. Pericarditis can occur as part of the postpericardiotomy syndrome after cardiac surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link\">",
"       \"Post-cardiac injury syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocarditis, in which chest pain typically occurs with concomitant pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coronary artery abnormalities, including congenital disorders or acquired conditions (eg, coronary artery aneurysm or stenosis caused by Kawasaki disease) (",
"      <a class=\"graphic graphic_table graphicRef58162 \" href=\"UTD.htm?9/47/9979\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80061 \" href=\"UTD.htm?18/60/19392\">",
"       image 1",
"      </a>",
"      ). Anomalous origin of the left coronary artery from the main pulmonary artery usually presents in infancy, but can become symptomatic later in childhood. In that disorder, left ventricular ischemia usually results in cardiomyopathy and mitral regurgitation.",
"     </li>",
"     <li>",
"      Ruptured sinus of Valsalva aneurysm, a rare condition caused by congenital absence of media in the aortic wall behind the sinus of Valsalva. The aneurysm typically ruptures into the right ventricle or right atrium but can affect the other chambers or pulmonary artery [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tachyarrhythmias (eg, supraventricular tachycardia with or without underlying Wolff-Parkinson-White syndrome, ventricular tachycardia), if sustained, may cause angina. Some children may describe the sensation of palpitations (caused by ventricular premature beats) as chest pain.",
"     </li>",
"     <li>",
"      Coronary vasospasm (variant angina) and myocardial infarction are rare causes of chest pain in children and adolescents. Coronary vasospasm is associated with transient ischemic changes on ECG, normal coronary arteriography, reversible septal akinesia by echocardiography, and cardiac enzyme elevation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"       \"Variant angina\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the United States, the incidence of acute myocardial infarction in adolescents is estimated as 6.6 events per 1 million patient-years resulting in 157 events per year [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/51\">",
"       51",
"      </a>",
"      ]. Myocardial infarctions occur more frequently in males and are associated with substance abuse and smoking. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Toxic exposure'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mitral valve prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether mitral valve prolapse is associated with chest pain is controversial. In one study of 119 children, 18 percent had atypical chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/52\">",
"     52",
"    </a>",
"    ]. However, in the Framingham Heart Study, the incidence of chest pain was not increased in 83 adults with mitral valve prolapse, compared with 3403 without the abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/53\">",
"     53",
"    </a>",
"    ]. Similarly, in a report of 813 children aged 9 to 14 years, 31 of whom had mitral valve prolapse, the incidence of chest pain was similar in affected and unaffected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Toxic exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to vasoconstrictive agents, such as cocaine, can cause chest pain that is likely of ischemic origin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Systemic hypertension, myocardial infarction, ventricular arrhythmias, myocarditis, and sudden death may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/57\">",
"     57",
"    </a>",
"    ]. Chest pain also has been associated with the use of marijuana [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/58\">",
"     58",
"    </a>",
"    ], methamphetamines, and sympathomimetic decongestants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cigarette smoking has been associated with chest pain in adults. In one study, chest pain reported by questionnaire in a sample of 70,208 adults was greater in smokers than nonsmokers (average excess 1.6-fold in men, 1.3-fold in women) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neurologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain rarely is caused by a neurologic disorder. Herpetic neuralgia in a dermatomal distribution on the chest can cause pain, which may be manifest before lesions appear (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    ). Spinal cord compression, which may be caused by tumor or vertebral collapse, or epidural abscess may cause radicular pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial proportion (21 to 45 percent) of cases of chest pain have no obvious cause after a thorough evaluation and are considered idiopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/2,5-8\">",
"     2,5-8",
"    </a>",
"    ]. Although repetitive episodes of pain may occur, symptoms typically resolve over time. In one report of 31 children with idiopathic chest pain followed for an average of 4.1 years, persistent symptoms were reported by 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/7\">",
"     7",
"    </a>",
"    ]. However, pain resolved in 81 percent of patients followed for more than three years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include a description of the pain and any associated symptoms. The patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parents should be asked about precipitating events, such as trauma, muscle strain, and foreign body ingestion, or stressful factors, such as a recent death in the family.",
"   </p>",
"   <p>",
"    Underlying medical conditions that may be associated with chest pain should be noted. These include asthma, cardiac disease, Kawasaki disease, and sickle cell disease.",
"   </p>",
"   <p>",
"    Family history should be obtained for genetic conditions with features that may lead to chest pain. Disorders including Marfan syndrome, Turner syndrome, and type IV Ehlers-Danlos syndrome predispose to aortic root dissection. Hypertrophic cardiomyopathy is a rare genetic disorder with familial and sporadic forms that may present with exertional chest pain.",
"   </p>",
"   <p>",
"    History should be sought about possible substance abuse, including cocaine ingestion and tobacco use. Use of other vasoactive drugs should be documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Description of chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain should be characterized by a thorough description. This includes the time course and duration, quality, location, radiation, severity, precipitating factors, and associated symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Temporal elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration and time course of the onset of chest pain may be a useful distinguishing feature. Chronic pain is unlikely to have a serious underlying cause and often has a musculoskeletal or psychogenic origin or is idiopathic.",
"   </p>",
"   <p>",
"    Acute pain is more likely to be caused by a medical condition. As examples, pain caused by pulmonary conditions (eg, reactive airway disease or pneumothorax) or vascular events (eg, aortic dissection or acute pulmonary embolism) typically has an abrupt onset. Ischemic myocardial pain, which is unusual in children, may have a gradual onset with increasing intensity over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A description of the quality of the pain may be helpful. The pain associated with costochondritis typically is described as midsternal in location and sharp in quality with minimal radiation. It occurs mainly at rest and lasts for seconds to a few minutes. The pain may increase in intensity with deep inspiration because of stretching of the costochondral junctions or muscle fibers.",
"   </p>",
"   <p>",
"    Patients with slipping rib syndrome may describe \"something slipping or giving away,\" \"a popping sensation,\" or \"hearing a clicking sound\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/18\">",
"     18",
"    </a>",
"    ]. In that condition, pain occurs with bending over or deep breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic cardiac pain may be described as squeezing, tightness, pressure, constriction, burning, or fullness in the chest. Pain caused by aortic root dissection is extremely severe. It is described as tearing in quality, and typically radiates to the back.",
"   </p>",
"   <p>",
"    Chest pain caused by pericarditis is sharp in quality, usually retrosternal in location and is often associated with radiation to the left shoulder. It is more severe in the supine position or with deep inspiration (because of pericardial distention). Pain may increase with swallowing if the pericardium near the esophagus is involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain that localizes to a small area on the chest more likely is of chest wall or pleural origin rather than visceral. Ischemic pain is a diffuse discomfort that may be difficult to localize.",
"   </p>",
"   <p>",
"    Radiation usually is associated with causes of pain that are uncommon in children. As an example, the pain of myocardial ischemia may radiate to the neck, throat, lower jaw, teeth, upper extremity, or shoulder. Other unusual causes include acute cholecystitis, which can present with right shoulder pain (although concomitant right upper quadrant or epigastric pain is more typical), aortic dissection, which may be associated with chest pain that radiates between the scapulae, or pericarditis that can radiate to the left shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be asked about factors that induce or make the pain worse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body position or movement, as well as deep breathing, may exacerbate chest pain of musculoskeletal origin.",
"     </li>",
"     <li>",
"      Pain made worse by swallowing likely is of esophageal origin. Discomfort that occurs with eating also may suggest upper gastrointestinal disease.",
"     </li>",
"     <li>",
"      Chest discomfort provoked by exertion often has a cardiac or respiratory cause.",
"     </li>",
"     <li>",
"      Pleuritic chest pain is worsened by breathing and may be exacerbated when lying down.",
"     </li>",
"     <li>",
"      Pain associated with coronary artery anomalies typically occurs with exertion due to limitations in myocardial oxygen delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated symptoms may help determine etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever, especially when associated with tachypnea or cough, may suggest a respiratory infection. Fever also can be present in patients with pericarditis, myocarditis, or Kawasaki disease. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Dyspnea may indicate pulmonary disorders, including pathology of the airways, lung parenchyma, or pulmonary vasculature, or be a sign of cardiac disease. In addition to chest pain, for example, patients with pulmonary embolism can develop dyspnea, hypoxemia, apprehension, cough, and diaphoresis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/42\">",
"       42",
"      </a>",
"      ]. Patients with myocarditis may have dyspnea and fatigue. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vomiting or regurgitation, painful swallowing, or heartburn associated with feeding suggest gastrointestinal disease, such as gastroesophageal reflux and esophagitis.",
"     </li>",
"     <li>",
"      Recurrent somatic complaints, including headache or abdominal or extremity pain, occur in most children with psychogenic chest pain [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Approximately one-third have significant sleep disturbances [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lightheadedness or paresthesias frequently accompany chest pain resulting from hyperventilation.",
"     </li>",
"     <li>",
"      Syncope or palpitations suggest an underlying cardiac disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"       \"Emergent evaluation of syncope in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough physical examination should be performed to detect findings associated with organic disease. Physical signs may indicate genetic conditions that include cardiac abnormalities. Fever suggests an infectious etiology.",
"   </p>",
"   <p>",
"    The remainder of the examination should focus on the chest. Patients with acute onset of chest pain and who are in distress require immediate management. This should be initiated while the evaluation proceeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal disorders, including costochondritis, are a major cause of chest pain in children and result in chest wall tenderness. Bruises associated with trauma sometimes are seen.",
"   </p>",
"   <p>",
"    Examination should include palpation of the costochondral junctions, the insertion site of the pectoralis major muscle group (by grasping the head of the muscle between the examiner's fingers and thumb), the inframammary area, and other regions of the chest where pain is reported. Involvement of the costochondral junctions often is asymmetric, with the left side more frequently affected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/3\">",
"     3",
"    </a>",
"    ]. The diagnosis is confirmed when palpation reproduces the discomfort.",
"   </p>",
"   <p>",
"    Diagnosis of slipping rib syndrome can be confirmed by the \"hooking\" maneuver in which the examiner's fingers are placed around the lower costal margin. Lifting anteriorly will elicit a click and reproduce pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tenderness on palpation of breast tissue often can be elicited in patients who complain of breast pain. Tender subareolar masses may be palpable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Respiratory signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of a respiratory etiology of chest pain may include tachypnea and respiratory distress. Diminished breath sounds over affected areas of the lung or rales may indicate pneumonia or pneumothorax, whereas wheezing may be audible in patients with asthma. Pneumomediastinum may produce subcutaneous emphysema that is detected as crepitus on palpation of the supraclavicular or neck region [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperventilation, associated with chest pain of psychogenic origin, may be present at the time of the examination. If not, it may be possible to reproduce the chest pain by asking the patient to hyperventilate. In general, hyperventilation must continue for at least 20 minutes to cause symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emergent evaluation of children and adolescents with respiratory distress is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cardiac signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardiac cause of chest pain may be suggested by abnormal heart sounds on auscultation (eg, cardiac murmur, pericardial friction rub) or by an abnormal pulse or blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Left ventricular outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of left ventricular outflow obstruction include a systolic ejection murmur at the right upper sternal border and occasionally along the left sternal border. Coarctation of the aorta is associated with elevated blood pressure in the arms and a lower blood pressure in the legs. If the coarctation is long-standing (present for more than five to seven years), collateral vessels may form that connect the upper and lower portions of the aorta; these vessels create a continuous murmur over the lateral aspect of the ribs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with pericarditis, pain increases when manual pressure is applied to the sternal region. The pain typically improves with sitting up and leaning forward. Signs of pericarditis depend upon the size of the pericardial effusion. Patients with a small effusion typically have an audible pericardial friction rub, caused by rubbing together of the inflamed parietal and visceral pericardial surfaces. The rub often is continuous in systole and diastole. It is easier to hear with the diaphragm of the stethoscope when the patient is sitting and leaning forward.",
"   </p>",
"   <p>",
"    A rub will not be heard if the effusion is large because the two pericardial surfaces of the pericardium are not in contact with each other. A large effusion may result in cardiac tamponade, manifested by a narrow pulse pressure, elevated pulsus paradoxus (&gt;10 mmHg), elevated jugular venous pressure, distant heart sounds, hepatomegaly, ascites, and peripheral edema.",
"   </p>",
"   <p>",
"    Signs of myocarditis include tachycardia, muffled heart sounds, a gallop rhythm, and a murmur of mitral regurgitation, usually accompanied by fever. Patients often complain of dyspnea and fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pulmonary hypertension typically have a right ventricular heave and a single loud S2. They may have a murmur consistent with tricuspid or pulmonary regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Mitral valve prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of mitral valve prolapse are a constant, mid-systolic apical click and occasionally an apical systolic murmur of mitral regurgitation. Both auscultatory findings are more prominent when the patient is in the standing rather than supine position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia may suggest supraventricular tachycardia. Cocaine ingestion may present with tachycardia, hypertension, and anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with chest pain have a normal physical examination or findings consistent with a musculoskeletal etiology. Further investigations are not needed in those cases.",
"   </p>",
"   <p>",
"    Diagnostic studies may help establish a diagnosis in patients with abnormal physical findings or with associated symptoms that suggest pulmonary or cardiac disease. Although cardiac causes of chest pain are uncommon in children, patients with anginal pain, pain with exertion that cannot be attributed to respiratory disease, or syncope should be referred to a pediatric cardiologist for further evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef61506 \" href=\"UTD.htm?20/33/21023\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80077 \" href=\"UTD.htm?16/17/16656\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph should be obtained in children in whom a cardiac or pulmonary disorder is suspected. Signs of cardiac enlargement may be apparent in conditions causing left ventricular outflow obstruction, heart failure, myocarditis, pericarditis, or pericardial effusion.",
"   </p>",
"   <p>",
"    Patients with pulmonary hypertension may have prominent main and central pulmonary arteries. The peripheral lung fields may be dark if pulmonary vascular resistance is chronically elevated.",
"   </p>",
"   <p>",
"    In patients with suspected pulmonary disorders, a chest radiograph may show infiltrates caused by pneumonia or areas of atelectasis and air trapping caused by aspiration of a foreign body. Hyperinflation typically is seen in patients with asthma. In addition, pneumothorax, pneumomediastinum, or pleural effusions can be detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ECG should be obtained if cardiac disease is suspected. In patients with a rapid pulse rate or palpitations, an ECG can identify the type of arrhythmia. If the arrhythmia is intermittent, a Holter monitor or event monitor recording may be needed.",
"   </p>",
"   <p>",
"    Other ECG abnormalities can help with diagnosis and indicate the need for further testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with left ventricular outflow obstruction may have evidence of left ventricular hypertrophy or strain. Formal exercise tolerance testing may be needed to assess the development of arrhythmia or ischemia during exertion.",
"     </li>",
"     <li>",
"      In pericarditis with effusion, the ECG changes during the clinical course. Generalized ST segment elevation involving limb and precordial leads is seen in the initial 10 to 14 days (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      ). This is followed by T wave flattening or inversion that can persist for an additional two weeks. Voltages will be reduced in amplitude if the effusion is large. Abnormal Q waves typically are not seen in pericarditis. ST-T wave abnormalities occur in myocarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children with anomalous origin of the left coronary artery, the typical ECG pattern is of an anterolateral infarction with deep and wide Q waves and T wave inversions in leads I, aVL, V5, and V6 (",
"      <a class=\"graphic graphic_waveform graphicRef72881 \" href=\"UTD.htm?32/58/33701\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with pulmonary hypertension typically have signs of right ventricular hypertrophy and right axis deviation. The ECG may show right ventricular strain (abnormal T waves in the anterior leads).",
"     </li>",
"     <li>",
"      ECG findings in pulmonary embolism usually are nonspecific ST-T segment changes or sinus tachycardia. If acute right ventricular hypertension occurs, the classic pattern of S wave in lead 1, Q wave, and T wave inversion in lead III can be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram will establish a diagnosis in cardiac disorders and help assess severity. This technique can be used to",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish the diagnosis of pulmonary hypertension and evaluate ventricular function and associated structural abnormalities.",
"     </li>",
"     <li>",
"      Determine the severity and site of left ventricular outflow obstruction and the level of ventricular function.",
"     </li>",
"     <li>",
"      Assess the size of a pericardial effusion and signs of tamponade, which include variation in Doppler peak velocity across the valves during the cardiac cycle, atrial free wall collapse, or ventricular septal paradoxical motion into the left ventricle during inspiration.",
"     </li>",
"     <li>",
"      Identify coronary artery abnormalities, including abnormal origin or course, fistula, or aneurysm or stenosis caused by Kawasaki disease.",
"     </li>",
"     <li>",
"      Diagnose aortic root dissection (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75705 \" href=\"UTD.htm?2/57/2960\">",
"       image 2",
"      </a>",
"      ). Alternatively, the diagnosis can be made with magnetic resonance imaging (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69616 \" href=\"UTD.htm?15/49/16144\">",
"       image 3",
"      </a>",
"      ), computed tomography, or aortography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55207 \" href=\"UTD.htm?10/14/10479\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81919 graphicRef58395 \" href=\"UTD.htm?42/44/43714\">",
"       image 5A-B",
"      </a>",
"      ). The most efficient imaging technique available at the institution should be used to establish the diagnosis.",
"     </li>",
"     <li>",
"      Diagnose ruptured sinus of Valsalva aneurysm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Gastrointestinal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with chest pain and gastrointestinal symptoms should be referred to a pediatric gastroenterologist. Evaluation of the upper gastrointestinal tract may reveal esophagitis, gastritis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    motility disorders such as diffuse esophageal spasm or achalasia. These abnormalities may be detected in some children with chest pain and no gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, a gastrointestinal evaluation should be considered in children with persistent chest pain and no obvious etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional testing should be based upon associated signs and symptoms and the results of the initial evaluation. Further evaluation may include pulmonary function testing in patients with respiratory disorders, a ventilation-perfusion scan to confirm the diagnosis of pulmonary embolism, or cardiac catheterization to evaluate coronary arteries or arrhythmia. An exercise tolerance test can be useful in patients with chest pain induced by exercise. Patients suspected of having an infection should have a complete blood count with differential and appropriate cultures. Toxicology screening should be performed if substance abuse is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute onset of chest pain and severe distress, abnormal vital signs, or hypoxemia require immediate intervention. Specific disorders (eg, asthma, pneumonia) should be treated appropriately. (see appropriate topics).",
"   </p>",
"   <p>",
"    Most patients with chronic chest pain require minimal intervention. Musculoskeletal pain typically responds to analgesics and rest, although frequently no medication is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic chest pain and associated symptoms that point to a specific diagnosis should be referred to an appropriate specialist for further evaluation. Children with gastrointestinal symptoms, or those with persistent or recurrent pain with no apparent etiology, should be referred to a gastroenterologist. Those with known cardiac disease or who have pain with exertion, syncope, dizziness, or palpitations should be referred to a cardiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Reassurance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reassurance is an important component of management. Although the etiology usually is benign, this symptom causes considerable anxiety in patients and their families because of the more serious implications of chest pain in adults. Cases with a psychogenic etiology may need additional counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain may persist or recur, although the natural history is not well described. One study reported follow-up of 407 patients with chest pain who were seen in an emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/8\">",
"     8",
"    </a>",
"    ]. Of the initial cohort, 149 (37 percent) were seen for at least six months and 51 (13 percent) for at least two years. Chest pain persisted in 43 percent of the group that was followed. A previously unrecognized organic etiology was identified in 12 patients, only one of whom had a cardiac abnormality (mitral valve prolapse); three had asthma. In another report of children with idiopathic chest pain, symptoms persisted in 19 percent followed for more than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27241/abstract/7\">",
"     7",
"    </a>",
"    ]. Follow-up should be provided until symptoms resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859080\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest pain is a common symptom in children and adolescents. Its underlying cause is typically benign in this patient population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Musculoskeletal causes (eg, costochondritis) comprise the largest category of known etiologies (",
"      <a class=\"graphic graphic_table graphicRef76014 \" href=\"UTD.htm?5/60/6092\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough history and physical examination usually can determine the cause and differentiate patients who require further diagnostic studies and acute intervention from those who can be managed with reassurance and continued follow-up. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chest pain who have a normal physical examination or findings consistent with a musculoskeletal etiology, no chest pain with exertion, and no fever do not need further cardiac investigation. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic studies (eg, electrocardiogram, chest radiograph, or echocardiogram) are warranted in patients with abnormal physical findings or with associated symptoms (eg, syncope, palpitations, dyspnea, fever, or chest pain associated with exertion) that suggest underlying pulmonary or cardiac disease (",
"      <a class=\"graphic graphic_algorithm graphicRef61506 \" href=\"UTD.htm?20/33/21023\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef80077 \" href=\"UTD.htm?16/17/16656\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although cardiac causes of chest pain are uncommon in children, patients with anginal pain, pain with exertion that cannot be attributed to respiratory disease, palpitations, or syncope should be referred to a pediatric cardiologist for further evaluation. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/1\">",
"      Selbst SM. Chest pain in children. Pediatrics 1985; 75:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/2\">",
"      Selbst SM, Ruddy RM, Clark BJ, et al. Pediatric chest pain: a prospective study. Pediatrics 1988; 82:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/3\">",
"      Brown RT. Costochondritis in adolescents. J Adolesc Health Care 1981; 1:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/4\">",
"      Brunswick AF, Boyle JM, Tarica C. Who sees the doctor? A study of urban black adolescents. Soc Sci Med Med Psychol Med Sociol 1979; 13A:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/5\">",
"      Pantell RH, Goodman BW Jr. Adolescent chest pain: a prospective study. Pediatrics 1983; 71:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/6\">",
"      Fyfe DA, Moodie DS. Chest pain in pediatric patients presenting to a cardiac clinic. Clin Pediatr (Phila) 1984; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/7\">",
"      Rowland TW, Richards MM. The natural history of idiopathic chest pain in children. A follow-up study. Clin Pediatr (Phila) 1986; 25:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/8\">",
"      Selbst SM, Ruddy R, Clark BJ. Chest pain in children. Follow-up of patients previously reported. Clin Pediatr (Phila) 1990; 29:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/9\">",
"      Driscoll DJ, Glicklich LB, Gallen WJ. Chest pain in children: a prospective study. Pediatrics 1976; 57:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/10\">",
"      Kocis KC. Chest pain in pediatrics. Pediatr Clin North Am 1999; 46:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/11\">",
"      Tunaoglu FS, Olgunt&uuml;rk R, Akcabay S, et al. Chest pain in children referred to a cardiology clinic. Pediatr Cardiol 1995; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/12\">",
"      Anzai AK, Merkin TE. Adolescent chest pain. Am Fam Physician 1996; 53:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/13\">",
"      Zavaras-Angelidou KA, Weinhouse E, Nelson DB. Review of 180 episodes of chest pain in 134 children. Pediatr Emerg Care 1992; 8:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/14\">",
"      Selbst SM. Evaluation of chest pain in children. Pediatr Rev 1986; 8:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/15\">",
"      Evangelista JA, Parsons M, Renneburg AK. Chest pain in children: diagnosis through history and physical examination. J Pediatr Health Care 2000; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/16\">",
"      Saleeb SF, Li WY, Warren SZ, Lock JE. Effectiveness of screening for life-threatening chest pain in children. Pediatrics 2011; 128:e1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/17\">",
"      Epstein SE, Gerber LH, Borer JS. Chest wall syndrome. A common cause of unexplained cardiac pain. JAMA 1979; 241:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/18\">",
"      Porter GE. Slipping rib syndrome: an infrequently recognized entity in children: a report of three cases and review of the literature. Pediatrics 1985; 76:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/19\">",
"      Mooney DP, Shorter NA. Slipping rib syndrome in childhood. J Pediatr Surg 1997; 32:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/20\">",
"      Taubman B, Vetter VL. Slipping rib syndrome as a cause of chest pain in children. Clin Pediatr (Phila) 1996; 35:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/21\">",
"      Heinz GJ, Zavala DC. Slipping rib syndrome. JAMA 1977; 237:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/22\">",
"      Coleman WL. Recurrent chest pain in children. Pediatr Clin North Am 1984; 31:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/23\">",
"      Pickering D. Precordial catch syndrome. Arch Dis Child 1981; 56:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/24\">",
"      Friedman SB. Conversion symptoms in adolescents. Pediatr Clin North Am 1973; 20:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/25\">",
"      Smith MS. Psychosomatic symptoms in adolescence. Med Clin North Am 1990; 74:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/26\">",
"      Asnes RS, Santulli R, Bemporad JR. Psychogenic chest pain in children. Clin Pediatr (Phila) 1981; 20:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/27\">",
"      Kashani JH, Lababidi Z, Jones RS. Depression in children and adolescents with cardiovascular symptomatology: the significance of chest pain. J Am Acad Child Psychiatry 1982; 21:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/28\">",
"      Neill WA, Hattenhauer M. Impairment of myocardial O2 supply due to hyperventilation. Circulation 1975; 52:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/29\">",
"      Wiens L, Sabath R, Ewing L, et al. Chest pain in otherwise healthy children and adolescents is frequently caused by exercise-induced asthma. Pediatrics 1992; 90:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/30\">",
"      Damore DT, Dayan PS. Medical causes of pneumomediastinum in children. Clin Pediatr (Phila) 2001; 40:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/31\">",
"      Stack AM, Caputo GL. Pneumomediastinum in childhood asthma. Pediatr Emerg Care 1996; 12:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/32\">",
"      Chalumeau M, Le Clainche L, Sayeg N, et al. Spontaneous pneumomediastinum in children. Pediatr Pulmonol 2001; 31:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/33\">",
"      Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: a 2002 update. J Pediatr 2002; 140:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/34\">",
"      Hall JR, Pyeritz RE, Dudgeon DL, Haller JA Jr. Pneumothorax in the Marfan syndrome: prevalence and therapy. Ann Thorac Surg 1984; 37:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/35\">",
"      Ravilly S, Robinson W, Suresh S, et al. Chronic pain in cystic fibrosis. Pediatrics 1996; 98:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/36\">",
"      Berezin S, Medow MS, Glassman MS, Newman LJ. Chest pain of gastrointestinal origin. Arch Dis Child 1988; 63:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/37\">",
"      Glassman MS, Medow MS, Berezin S, Newman LJ. Spectrum of esophageal disorders in children with chest pain. Dig Dis Sci 1992; 37:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/38\">",
"      Long WB, Cohen S. The digestive tract as a cause of chest pain. Am Heart J 1980; 100:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/39\">",
"      Bernstein D, Coupey S, Schonberg SK. Pulmonary embolism in adolescents. Am J Dis Child 1986; 140:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/40\">",
"      Buck JR, Connors RH, Coon WW, et al. Pulmonary embolism in children. J Pediatr Surg 1981; 16:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/41\">",
"      Goldsby RE, Saulys AJ, Helton JG. Pediatric pulmonary artery thromboembolism: an illustrative case. Pediatr Emerg Care 1996; 12:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/42\">",
"      Evans DA, Wilmott RW. Pulmonary embolism in children. Pediatr Clin North Am 1994; 41:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/43\">",
"      Brenner JI, Ringel RE, Berman MA. Cardiologic perspectives of chest pain in childhood: a referral problem? To whom? Pediatr Clin North Am 1984; 31:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/44\">",
"      Graneto JW, Turnbull TL, Marciniak SA. An unusual cause of chest pain in an adolescent presenting to the emergency department. Pediatr Emerg Care 1997; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/45\">",
"      Vaughan CJ, Casey M, He J, et al. Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. Circulation 2001; 103:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/46\">",
"      Ratnapalan S, Brown K, Benson L. Children presenting with acute pericarditis to the emergency department. Pediatr Emerg Care 2011; 27:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/47\">",
"      Karaaslan T, Gudinchet F, Payot M, Sekarski N. Congenital aneurysm of sinus of valsalva ruptured into right ventricle diagnosed by magnetic resonance imaging. Pediatr Cardiol 1999; 20:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/48\">",
"      Ivy D, Kaye J, Flitter D, Wiggins J. Variant angina in an adolescent. Pediatr Cardiol 1994; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/49\">",
"      Wilkes D, Donner R, Black I, Carabello BA. Variant angina in an 11 year old boy. J Am Coll Cardiol 1985; 5:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/50\">",
"      Perry RF, Garlisi AP, Allison EJ, et al. Acute myocardial infarction in a 16-year-old boy with no predisposing risk factors. Pediatr Emerg Care 1997; 13:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/51\">",
"      Mahle WT, Campbell RM, Favaloro-Sabatier J. Myocardial infarction in adolescents. J Pediatr 2007; 151:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/52\">",
"      Bisset GS 3rd, Schwartz DC, Meyer RA, et al. Clinical spectrum and long-term follow-up of isolated mitral valve prolapse in 119 children. Circulation 1980; 62:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/53\">",
"      Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/54\">",
"      Arfken CL, Lachman AS, McLaren MJ, et al. Mitral valve prolapse: associations with symptoms and anxiety. Pediatrics 1990; 85:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/55\">",
"      Hollander JE, Todd KH, Green G, et al. Chest pain associated with cocaine: an assessment of prevalence in suburban and urban emergency departments. Ann Emerg Med 1995; 26:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/56\">",
"      Woodward GA, Selbst SM. Chest pain secondary to cocaine use. Pediatr Emerg Care 1987; 3:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/57\">",
"      Isner JM, Estes NA 3rd, Thompson PD, et al. Acute cardiac events temporally related to cocaine abuse. N Engl J Med 1986; 315:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/58\">",
"      Lantner, IL. Adolescent chest pain (letter). Pediatrics 1983; 72:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27241/abstract/59\">",
"      Friedman GD, Siegelaub AB, Dales LG. Cigarette smoking and chest pain. Ann Intern Med 1975; 83:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6469 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27241=[""].join("\n");
var outline_f26_38_27241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2859080\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Musculoskeletal conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Costochondritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Slipping rib syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Precordial catch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychogenic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Breast causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Respiratory disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Acute chest syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiac conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neurologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Description of chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Temporal elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Quality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Chest wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Respiratory signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cardiac signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Left ventricular outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Gastrointestinal evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Reassurance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2859080\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6469|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/33/21023\" title=\"algorithm 1\">",
"      Eval chest pain normal exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/17/16656\" title=\"algorithm 2\">",
"      Eval chest pain abnormal exam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6469|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/60/19392\" title=\"diagnostic image 1\">",
"      Angiogram coronary a fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/57/2960\" title=\"diagnostic image 2\">",
"      Ascending aortic dissection on echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/49/16144\" title=\"diagnostic image 3\">",
"      Aortic dissection on magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/14/10479\" title=\"diagnostic image 4\">",
"      Aortogram showing descending thoracic aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/26/7584\" title=\"diagnostic image 5A\">",
"      Thoracic aortic dissection on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/51/36670\" title=\"diagnostic image 5B\">",
"      Thoracic aortic dissection on reconstructed computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/6/11371\" title=\"table 1\">",
"      Understanding chest pain sx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/60/6092\" title=\"table 2\">",
"      Etiology pediatric chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/4/28748\" title=\"table 3\">",
"      Etiology pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/47/9979\" title=\"table 4\">",
"      Coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6469|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/53/43866\" title=\"waveform 1\">",
"      ECG in pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?32/58/33701\" title=\"waveform 2\">",
"      ECG anomalous left coronary a",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_38_27242="Overview of idiopathic environmental intolerance (multiple chemical sensitivity)";
var content_f26_38_27242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27242/contributors\">",
"     Donald W Black, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27242/contributors\">",
"     Scott Temple, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27242/contributors\">",
"     Joel Dimsdale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/38/27242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/38/27242/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/38/27242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic environmental intolerance (IEI), formerly called multiple chemical sensitivity, is a subjective illness marked by recurrent, nonspecific symptoms attributed to low levels of chemical, biologic, or physical agents. These symptoms occur in the absence of consistent objective diagnostic physical findings or laboratory tests that define an illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Many experiments and observational studies consistently identify psychopathology in patients with IEI, and implicate behavioral or psychiatric causes for this illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3\">",
"     3",
"    </a>",
"    ]. This indicates that the underlying illness in many cases of IEI is actually a psychiatric disorder, such as a somatoform, depressive, or anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic provides an overview of IEI, including clinical management of this condition. Related topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=see_link\">",
"     \"Primary care management of medically unexplained symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IEI typically report sensitivity to multiple, chemically unrelated substances and becoming ill with heterogeneous, nonspecific symptoms when exposed to low concentrations of chemicals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Patients attempt to minimize exposure by modifying their lives, sometimes in far reaching ways.",
"   </p>",
"   <p>",
"    These \"chemically sensitive\" people are sometimes treated by \"clinical ecologists\" or \"environmental clinicians\" who believe the disorder is acquired, highly prevalent in the general population, and goes unrecognized by most other clinicians.",
"   </p>",
"   <p>",
"    The most frequently used term for this condition is \"multiple chemical sensitivity,\" but many other terms have also been used, including \"environmental illness.\" The World Health Organization in 1996 proposed the term \"idiopathic environmental intolerance\" (IEI) be used instead, because it avoids unsubstantiated assumptions of etiology, and many people attribute symptoms to environmental agents other than chemicals, such as food or electromagnetic forces [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criticisms of IEI as a distinct medical entity include the lack of reliable case definitions; the lack of consistent physical abnormalities and reproducible laboratory results; the use of unorthodox diagnostic procedures; and the use of unproven and potentially harmful treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, much of the research into IEI has been problematic due to excessive reliance upon surveys and self-reported symptoms, selection bias, lack of blinding, and inconsistent quality assurance of laboratory determinations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicity due to certain chemicals such as lead and arsenic is well established, including the signs, symptoms, and pathophysiology of the disease states that occur following exposure. No such information exists for IEI despite many years of research.",
"   </p>",
"   <p>",
"    Prominent medical societies view IEI with marked skepticism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1,2,10-13\">",
"     1,2,10-13",
"    </a>",
"    ]. As an example, the American Medical Association concluded that, \"Until such accurate, reproducible, and well-controlled studies are available, the American Medical Association Council on Scientific Affairs believes that multiple chemical sensitivity should not be considered a recognizable syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychiatric problems are present in most cases of IEI. The psychiatric basis for the illness does not negate the suffering and disability that occurs in these patients, and clinicians should remember that all psychiatric illness is ultimately a disorder of brain biology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys show that many people report unusual sensitivity to everyday chemicals, but they do not tell us whether the complaints are clinically significant. As an example, the data do not distinguish between mild annoyance at cigarette smoke and a severe asthmatic reaction. IEI covers a broad range of symptoms, and it is not at all clear that people who report chemically sensitivities in a telephone survey resemble those who seek medical care for complaints of IEI.",
"   </p>",
"   <p>",
"    A review found that IEI is reported only in Western industrialized societies and is unknown in other countries, despite the ubiquitous presence of chemicals to which the illness is attributed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only nationally representative study of IEI, conducted in Germany, found self-reported chemical sensitivity in 9 percent of the population, and a physician diagnosis of IEI in 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/15\">",
"     15",
"    </a>",
"    ]. Studies in US communities found rates of self-reported chemical sensitivity ranging from 13 to 33 percent, and a prevalence of physician-diagnosed IEI in 3 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,16-18\">",
"     3,16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of sociodemographic variables associated with IEI have found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age for patients seen in clinical settings is typically in the 30s or 40s [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/18-36\">",
"       18-36",
"      </a>",
"      ]. Adults 65 years and older are less likely to identify themselves as chemically sensitive, compared to those who are younger [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/6\">",
"       6",
"      </a>",
"      ]. Patient-reported symptom onset is often 10 to 15 years prior to presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/6,18\">",
"       6,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IEI is more prevalent in women than men [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,6,15,16,18-39\">",
"       3,6,15,16,18-39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Individuals who never married are significantly less likely to receive a diagnosis of IEI by a physician, compared to those who are married (OR 0.56) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/16,35\">",
"       16,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Race and ethnicity has not been well studied. Hispanic ethnicity was significantly associated with physician diagnosis of IEI in one survey (OR 1.82) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Employment, income, and education are variably related to IEI. While population surveys have generally found that employment, income, and education are not significantly associated with the prevalence of IEI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/6,16\">",
"       6,16",
"      </a>",
"      ], patients seen in clinical settings are typically middle to lower class and well educated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/19-32,35,40\">",
"       19-32,35,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Health care utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled studies demonstrate that patients with IEI symptoms use significantly more health care resources [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/27,32\">",
"     27,32",
"    </a>",
"    ]. A cross-sectional study found that significantly more patients with IEI symptoms than controls visited an outpatient physician at least six times during the prior year (26 versus 10 percent), visited an emergency department at least once (45 versus 21 percent), or were hospitalized at least once (16 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychosocial functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies show that functional impairment (occupation, relationships, and leisure) is significantly greater for patients with IEI symptoms than for controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/27,32\">",
"     27,32",
"    </a>",
"    ]. A prospective study found these differences persisted at 32 months post baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/28\">",
"     28",
"    </a>",
"    ]. Functioning is poor because attempts to avoid alleged chemical triggers often result in loss of work and isolation from family and friends.",
"   </p>",
"   <p>",
"    A one-year prospective study of 49 patients with IEI symptoms and 54 controls found patients were significantly more likely to have lost a job or stopped working (22 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/27\">",
"     27",
"    </a>",
"    ]. Other studies found that 15 to 77 percent of patients had stopped working temporarily or left a job because of their chemical sensitivities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/25,29,32-34\">",
"     25,29,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies have found that patients with IEI symptoms have significantly poorer social functioning compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/25,32,35\">",
"     25,32,35",
"    </a>",
"    ]. In one study, 91 percent of patients had reduced contact with friends and 63 percent had reduced contact with family [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other serious disruptions can occur. Patients take special precautions at home, adhere to special diets, limit travel, experience difficulty shopping in stores or eating in restaurants, and change their residence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/27,29\">",
"     27,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is some disagreement whether IEI is a toxigenic or psychogenic illness, the evidence strongly demonstrates there is no immunologic or other biologic basis for IEI and that psychopathology causes the symptoms of IEI in at least some if not most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/14,41-47\">",
"     14,41-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887502\">",
"    <span class=\"h2\">",
"     Toxicogenic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical ecologists have generated many hypotheses explaining how toxins cause IEI symptoms. However, controlled studies show that the immune system is not involved and that immunologic tests are not diagnostic of IEI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]. In addition, there are no empirical data to support other proposed mechanisms involving toxicology or oxidative damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/2,48\">",
"     2,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple review studies have consistently failed to find a systematic connection between exposure to environmental triggers and onset of IEI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,33,49,50\">",
"     3,33,49,50",
"    </a>",
"    ]. Provocation studies that exposed patients with IEI to different substances found that patients could not distinguish between active and placebo substances when blinding or masking was adequate. Some patients with IEI exhibited severe reactions to sham provocations, which in one study were so extreme that the trial had to be terminated. These findings indicate that the biological properties of the various implicated chemicals do not cause IEI symptoms.",
"   </p>",
"   <p>",
"    The notion that IEI symptoms result from toxic chemical substances is not consistent with the level of exposure, which is far below the established level of toxicity. In addition, the suspected chemicals are common in the environment and well tolerated by the general population.",
"   </p>",
"   <p>",
"    While it is clearly established that infectious microorganisms, allergens, and toxins can cause diseases (eg, asthma, rhinitis) that are accompanied by objective changes of bronchial or nasal function, IEI is marked only by subjective symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies have attempted to find biologic correlates or markers of IEI, eg, electroencephalography or brain imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, none of these studies carefully selected subjects or used appropriate controls, the results were not specific to patients with IEI, and the results have not been consistently replicated in patients with IEI symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887516\">",
"    <span class=\"h2\">",
"     Psychogenic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high prevalence of psychiatric morbidity observed in patients with IEI supports the theory that psychopathology causes at least some cases of IEI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. In addition, a study of family psychiatric history in patients with IEI found first-degree relatives of patients were significantly more likely than relatives of controls to have depression (17 versus 7 percent), alcoholism (20 versus 6 percent), and antisocial personality disorder (8 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Psychiatric disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    IEI symptoms appear to stem from underlying psychiatric disease rather than any acute effect of chemical exposure. This was demonstrated in a study of 59 industrial workers exposed to low doses of metals and solvents on a daily basis (control group) and 300 patients with IEI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/54\">",
"     54",
"    </a>",
"    ]. Although controls and IEI patients had similar serum concentrations of solvents and controls had higher urine metal concentrations, the patients had significantly higher rates of psychiatric diagnoses and distress.",
"   </p>",
"   <p>",
"    Some clinical ecologists argue that IEI causes psychopathology in the same manner as a chronic disease such as diabetes. This is contradicted by the finding that psychiatric disorders typically occur prior to the onset of IEI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/22,24,27,37,43\">",
"     22,24,27,37,43",
"    </a>",
"    ]. One multicenter study found that mental disorders predated the onset of IEI symptoms by a mean average of 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several other plausible hypotheses explaining how psychogenic factors cause IEI. None of these are mutually exclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887533\">",
"    <span class=\"h2\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several provocation studies indicate that some patients with IEI symptoms have a predisposition to anxiety disorders and that anxiety may be a causal mechanism in at least some cases of IEI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/36,55-57\">",
"     36,55-57",
"    </a>",
"    ]. One study compared 31 patients with IEI and 31 normal healthy controls by administering a single-breath inhalation of 35 percent carbon",
"    <span class=\"nowrap\">",
"     dioxide/65",
"    </span>",
"    per cent oxygen, a reliable trigger of experimental panic in patients with panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/36\">",
"     36",
"    </a>",
"    ]. Significantly more patients with IEI suffered a panic attack compared to the healthy controls (71 versus 26 percent). A different provocation challenge study exposed 15 patients to their self-reported chemical \"trigger\" substances, which induced hyperventilation in 73 percent along with a rapid fall in pCO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genetic study found that the cholecystokinin B receptor allele 7, which is associated with panic disorder, was found in significantly more patients than controls (41 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887550\">",
"    <span class=\"h2\">",
"     Conditioned response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic and operant conditioning may account for symptoms of IEI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1,14,59\">",
"     1,14,59",
"    </a>",
"    ]. The theorized process begins with exposure to toxic or excess doses of a strong smelling chemical irritant that serves as the unconditioned stimulus. This is followed by the unconditioned response in the form of a physical or psychologic reaction. The same odor at a much lower concentration then serves as the conditioned stimulus and will trigger a conditioned response, with the same symptoms. Through stimulus generalization, different odors or irritants precipitate similar symptoms. Patients reduce their symptoms by avoiding the triggering chemicals and associated odors, and this negative reinforcement maintains the symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887562\">",
"    <span class=\"h2\">",
"     Symptom amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who learn about IEI may attribute their previously ill-defined chronic symptoms to this illness, which they regard as serious [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/60\">",
"     60",
"    </a>",
"    ]. This misinterpretation intensifies the symptoms, which then leads to greater self-scrutiny [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/60\">",
"     60",
"    </a>",
"    ]. Other ambiguous physical sensations are then viewed as further evidence of IEI. Thus, patient attention to benign but distressing physical sensations may be amplified through progressive preoccupation with symptoms, which is fueled by medical scrutiny, public health concern, and inappropriate media attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887578\">",
"    <span class=\"h2\">",
"     Iatrogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;IEI may be iatrogenic in some patients because clinical ecologists assess patients with the goal of explaining symptoms in terms of their connection to environmental chemicals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1\">",
"     1",
"    </a>",
"    ]. It is possible that some patients become convinced they have IEI through the power of suggestion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of studies have demonstrated that suggestion and expectation cause somatic symptoms in otherwise healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,61,62\">",
"     3,61,62",
"    </a>",
"    ]. One study demonstrated that in healthy volunteers who were exposed to an odor that was characterized as harmful, healthy, or neutral, those who were informed the odor was harmful reported significantly more symptoms (eg, dizziness or headache) compared to those given a neutral or healthy bias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the use of diagnostic tests and treatments may unintentionally reinforce symptoms or even increase the number of symptoms, thus exacerbating a patient's sense of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,22\">",
"     3,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887613\">",
"    <span class=\"h2\">",
"     Cognitive processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problematic cognitive styles may lead patients to somaticize when faced with adversity. Patients with IEI symptoms have externally oriented thinking and limited self-awareness, with a tendency to identify an environmental source of their symptoms and misattribute the symptoms to that external source [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, biased attention and reasoning may lead to misattribution and misinterpretation of physical sensations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887597\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known to what extent trauma is a risk factor for IEI. A study compared female patients with IEI symptoms to a control group of women who each had a chronic illness plus an anxiety or mood disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/66\">",
"     66",
"    </a>",
"    ]. Significantly more patients with IEI reported a history of sexual abuse (60 versus 25 percent) and physical abuse (50 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/66\">",
"     66",
"    </a>",
"    ]. However, a different study compared patients with IEI and controls, and found no significant difference in the number within each group who had a history of trauma (48 versus 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, another study found that only 1 percent of 295 patients with IEI met criteria for posttraumatic stress disorder using a structured interview [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2887585\">",
"    <span class=\"h2\">",
"     Coping mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may avoid taking responsibility for their occupational, marital, and social problems and instead, cope with them by attributing them to IEI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/26\">",
"     26",
"    </a>",
"    ]. Assuming the sick role may provide certain rights and privileges that relieve the patient of undesired obligations. Somatization may be used as a means of communicating emotional distress. In addition, somatization may be used as a coping strategy in order to gratify dependency needs and the wish to be cared for by others, obtain social contact through doctor visits or support groups, manipulate interpersonal relationships, and compensate for having little control over others [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study found that expressing feelings, especially negative ones, was significantly more difficult for patients with IEI compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/26\">",
"     26",
"    </a>",
"    ]. This supports the idea that patients with IEI express their emotional distress and seek help through physical symptoms, perhaps because there is less stigma associated with nonpsychiatric illnesses, or because patients have limited verbal skills and psychologic understanding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/68\">",
"     68",
"    </a>",
"    ]. A review found that IEI patients are more defensive, tend to deny psychopathology, and express distress through somatization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of IEI are diffuse, nonspecific, ambiguous, and common in the general population. There is no characteristic set of symptoms for IEI that can be distilled from the heterogeneous complaints involving a wide range of organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef57038 \" href=\"UTD.htm?5/35/5692\">",
"     table 1",
"    </a>",
"    ). In one study, 295 patients with IEI reported 252 different symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no essential differences in symptoms between patients who meet criteria for IEI and those who do not. A multicenter study of 290 patients treated at environmental medicine clinics compared the subset that met criteria for IEI according to their physician against the subset who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/33\">",
"     33",
"    </a>",
"    ]. There were no significant differences in the proportion of IEI patients versus non-IEI patients who reported respiratory (29 versus 30 percent), musculoskeletal (35 versus 39 percent), cardiovascular (14 versus 11 percent), gastrointestinal (38 versus 26 percent), dermatologic (24 versus 26 percent), head and sensory (34 versus 36 percent), and general (74 versus 68 percent) symptoms.",
"   </p>",
"   <p>",
"    Patients with IEI commonly report cognitive impairment. As an example, significantly more patients with IEI reported poor concentration or memory in the year prior to assessment, compared to controls (87 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/29\">",
"     29",
"    </a>",
"    ]. However, objective assessment of neuropsychologic functioning with standardized tests in patients with IEI reveals little or no impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/27,29,50,69\">",
"     27,29,50,69",
"    </a>",
"    ]. As an example, a battery of nine tests, which evaluated attention, concentration, memory, mental flexibility, and visual motor speed, was administered to 41 patients with IEI. The results showed that all of the scores fell within an average range for age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, the scores were essentially the same compared to a control group of patients with chronic musculoskeletal injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chemical exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;IEI symptoms often develop following a single massive chemical exposure such as accidentally being sprayed with pesticides. Other patients report intermittent or chronic exposure to low levels of chemicals such as repeated sprayings of pesticides around the home, or exposure to new carpeting or new furniture. Thus, exposure may last anywhere from seconds to years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemical sensitivities are generally attributed to numerous unrelated compounds, but emphasis is usually placed on volatile synthetic compounds such as gasoline, paints, and perfumes. Foods, yeast, electromagnetic radiation, and metals such as mercury amalgam fillings have also been alleged to cause IEI symptoms.",
"   </p>",
"   <p>",
"    In one study, patients reported sensitivity to a mean of 79 substances [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/18\">",
"     18",
"    </a>",
"    ]. Many clinical ecologists attribute this to a \"spreading phenomenon\" in which sensitivity to one agent leads to additional sensitivities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/70\">",
"     70",
"    </a>",
"    ]. There is no plausible explanation for such a process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CASE DEFINITIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no definitive case definition or set of diagnostic criteria for IEI. Several proposed case definitions for IEI emphasize reported sensitivity to multiple unrelated compounds, signs or symptoms in multiple organ systems, and symptom resolution upon withdrawal of the presumed chemical incitant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/16,37,48,70,71\">",
"     16,37,48,70,71",
"    </a>",
"    ]. Cullen's definition is one that is widely used (",
"    <a class=\"graphic graphic_table graphicRef60215 \" href=\"UTD.htm?7/0/7179\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/71\">",
"     71",
"    </a>",
"    ]. An alternative is the working definition of IEI developed at a symposium convened by the World Health Organization and German government agencies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An acquired disorder with multiple recurrent symptoms",
"     </li>",
"     <li>",
"      Associated with diverse environmental factors tolerated by the majority of people",
"     </li>",
"     <li>",
"      Not explained by any known medical, psychiatric, or psychologic disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither these nor any other case definition has been established as valid diagnostic criteria. The reason is that identification of cases is extremely problematic and inconsistent, even when a set of uniform case criteria are applied. As an example, a federally sponsored research network of environmental medicine clinics at five academic centers collaboratively studied IEI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/33\">",
"     33",
"    </a>",
"    ]. The study developed an explicit protocol for physicians to identify cases using Cullen's case criteria (",
"    <a class=\"graphic graphic_table graphicRef60215 \" href=\"UTD.htm?7/0/7179\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/71\">",
"     71",
"    </a>",
"    ]. The proportion of clinic patients who were classified as meeting criteria for IEI varied between 0 to 81 percent among the five research centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Unvalidated testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical ecologists may conduct tests, such as elimination diets and oral food challenges to test for specific food sensitivities. Provocation-neutralization testing is also used to test for specific chemical sensitivities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/22\">",
"     22",
"    </a>",
"    ]. Small amounts of dilute chemical are taken sublingually, by injection, or through inhalation in a special glass booth. After this provocation, patients record their subjective symptoms, such as lightheadedness or shortness of breath. These symptoms are then \"neutralized\" by applying a smaller dose of the same substance. These tests have been criticized because they are rarely conducted in a blinded fashion or with the use of placebo controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1,17,72\">",
"     1,17,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunologic tests measuring serum immunoglobulins and complement levels may be conducted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/2,73\">",
"     2,73",
"    </a>",
"    ]. Assays of various chemicals including organic solvents, hydrocarbons, pesticides, and heavy metals are sought in samples of blood, urine, fat, hair, or other tissues. These testing procedures have been criticized because no laboratory abnormalities have been reliably linked to IEI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PSYCHIATRIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The belief that chemicals cause IEI symptoms is an overvalued idea, which means patients maintain their conviction despite substantial evidence to the contrary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/26\">",
"     26",
"    </a>",
"    ]. Multiple reviews of experiments and observational studies consistently implicate psychiatric causes for IEI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,14,41-47\">",
"     3,14,41-47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition and background'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with IEI symptoms are heterogeneous, and not all cases can necessarily be attributed to psychogenic causes. Studies using standardized, structured clinical interviews showed that 25 percent of patients with IEI symptoms did not meet criteria for a current or past psychiatric disorder, and 24 percent did not have clinically significant psychiatric distress [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/27,34\">",
"     27,34",
"    </a>",
"    ]. Thus, patients with IEI symptoms have significantly more psychiatric morbidity than is observed in control populations, but less than what is expected for a clinical psychiatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence rates of psychiatric disorders reported in studies probably underestimate the true rates because many of the instruments used to assess psychopathology are transparent in their content and patients with IEI symptoms are often reluctant to acknowledge psychiatric symptoms and distress [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychiatric diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of mental disorders in patients with IEI is high [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/44\">",
"     44",
"    </a>",
"    ]. Studies using standardized, structured psychiatric interviews found that 65 to 75 percent of patients with IEI symptoms met criteria for a lifetime (current or past) psychiatric disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/25,34\">",
"     25,34",
"    </a>",
"    ]. This compares to a lifetime prevalence in the general population of 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/75\">",
"     75",
"    </a>",
"    ]. Patients may have more than one psychiatric diagnosis; in one study, 295 patients with IEI symptoms met criteria for 435 diagnoses (",
"    <a class=\"graphic graphic_table graphicRef74174 \" href=\"UTD.htm?36/21/37213\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of five studies that each used standardized, structured diagnostic interviews found the most frequently identified psychiatric diseases in patients with IEI symptoms were [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Somatoform disorders",
"     </li>",
"     <li>",
"      Mood disorders",
"     </li>",
"     <li>",
"      Anxiety disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Somatoform disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence indicates that many patients with IEI symptoms actually suffer from a somatoform disorder. Studies using standardized, structured psychiatric interviews have found somatoform disorders in 26 to 69 percent of patients with IEI symptoms, and consistently found somatoform disorders significantly more often in patients with IEI symptoms than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/23,26,31\">",
"     23,26,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H2#H2\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of IEI often resemble the specific diagnosis of undifferentiated somatoform disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/4,40\">",
"     4,40",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef73919 \" href=\"UTD.htm?23/27/23995\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A study found that 54 patients with IEI symptoms and 44 patients with somatoform disorders did not differ significantly in clinical features such as number of visits to a family physician [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/31,76\">",
"     31,76",
"    </a>",
"    ]. In addition, patients with IEI reported nearly the same number of somatic symptoms as the group with somatoform disorder, and significantly more somatic symptoms than the control group, both at baseline and at prospective follow-up 32 months post baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mood and anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using the Structured Clinical Interview for DSM-IV found 17 to 30 percent of patients with IEI symptoms met criteria for either a current or lifetime mood disorder, while anxiety disorders were found in 17 to 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/31,34,54\">",
"     31,34,54",
"    </a>",
"    ]. One such study compared 309 patients with IEI symptoms and 59 controls and found significantly more patients had a lifetime mood disorder (30 versus 12 percent) or a lifetime anxiety disorder (20 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression is most common. A structured telephone interview using standardized instruments found significantly higher rates of current depressive disorders in 169 military personnel with IEI compared to 3526 personnel without IEI (56 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Personality disorders &mdash; A study using a standardized, structured psychiatric interview compared 23 patients with IEI symptoms to 46 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Significantly more patients than controls met criteria for at least one lifetime personality disorder (74 versus 28 percent). Specifically, IEI patients were more likely to meet criteria for schizotypal, histrionic, narcissistic, dependent, avoidant, and obsessive-compulsive personality disorders.",
"     </li>",
"     <li>",
"      Psychotic disorders &mdash; One study found the lifetime prevalence of psychotic disorders (primarily delusional disorder) in patients with more severe forms of IEI was 13 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Substance use disorders &mdash; Patients with IEI symptoms do not have an increased risk for substance use disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/25,36,37\">",
"       25,36,37",
"      </a>",
"      ]. A structured telephone interview using standardized instruments found little difference in the prevalence rate of alcohol abuse between 169 military personnel with IEI compared to 3526 personnel without IEI (17 versus 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Psychiatric distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with IEI symptoms who do not meet criteria for a psychiatric disorder nevertheless have psychiatric symptoms and traits. One study using standardized, structured psychiatric interviews found a significantly greater mean number of psychiatric symptoms in 23 patients with IEI compared to 46 general population controls (28 versus 9 symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies using standardized interviews and scales (eg, Minnesota Multiphasic Personality Inventory-2, Symptom Checklist 90-Revised) consistently identify somatic, depressive, and anxious features in significantly more patients with IEI symptoms than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/26,27,29,33,36,54,74\">",
"     26,27,29,33,36,54,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with IEI symptoms may have externally oriented thinking, difficulty with self-reflection, and less emotional insight. This may lead to difficulties identifying and expressing feelings, sensations, and opinions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MEDICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive evaluation of patients with IEI symptoms includes a history, physical examination, and laboratory tests (",
"    <a class=\"graphic graphic_table graphicRef77187 \" href=\"UTD.htm?13/54/14188\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A thorough history should include the signs and symptoms which the patient attributes to IEI, the onset of the disorder, alleged triggering events, how the patient became aware of the diagnosis, the diagnostic techniques and treatments used, and the patient's response to treatment. The clinician also needs to make a detailed assessment of the patient's psychiatric history [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed occupational and environmental history should be obtained because patients often report that symptoms stem from chemical exposures. Consultation with an occupational medicine specialist may be helpful.",
"   </p>",
"   <p>",
"    IEI should be distinguished from objectively defined physical illnesses, such as allergies and contact dermatitis. In addition, the differential diagnosis includes medical disorders with nonspecific motor and sensory abnormalities or transient or equivocal signs (eg, multiple sclerosis, systemic lupus erythematosus, acute intermittent porphyria, and hemochromatosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of a proper assessment was illustrated by a study of 264 patients with IEI symptoms who were evaluated at an outpatient environmental medicine clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/4\">",
"     4",
"    </a>",
"    ]. Standard procedure included an extensive case history, physical examination, routine laboratory tests, and monitoring for toxic substances. The evaluation identified various diseases (eg, polyneuropathy, multiple sclerosis) in many of the patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laboratory and medical tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment should include a complete blood count, serum electrolytes, serum glucose, and urine analysis.",
"   </p>",
"   <p>",
"    The selection of other tests will be guided by the patient's signs and symptoms. For example, patients with prominent respiratory tract complaints may need referral for pulmonary function tests to rule out the presence of reactive airway disease. If the patient's symptoms appear to be caused by specific allergies, or if the patient has received a diagnosis of \"environmental allergies\" or \"immune dysregulation,\" routine skin testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in vivo assays can help to rule out the presence of an allergic state [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The legitimate use of tests needs to be balanced against excessive testing that is repetitious or not indicated. Physicians should thus use caution in ordering tests and obtaining specialty consults for the purpose of reassuring the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/60\">",
"     60",
"    </a>",
"    ]. A review found that negative findings do not reassure most patients with chronic medically unexplained symptoms and may paradoxically increase anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Psychiatric assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychiatric assessment will probably yield evidence of a somatoform, mood, anxiety, or other disorder. The clinician can use a brief screening instrument to assess patients, such as the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/80\">",
"     80",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef82674 \" href=\"UTD.htm?21/32/22019\">",
"     table 6",
"    </a>",
"    ). This instrument screens for and provides categorical DSM-IV diagnoses for somatoform, depressive, anxiety, alcohol, and eating disorders. It was specifically designed for use in primary care, is fully self-administered by the patient, has good diagnostic validity (sensitivity 75 percent, specificity 90 percent), and the median physician time to review the results is one to two minutes.",
"   </p>",
"   <p>",
"    Self-report instruments have the advantage of saving interviewer time but are more prone to false positive diagnoses. Alternatively, clinicians may use a structured diagnostic interview such as the Structured Clinical Interview for DSM-IV, which enables the interviewer to clarify ambiguous or contradictory responses, but are labor intensive and generally reserved for specialized treatment or research settings.",
"   </p>",
"   <p>",
"    Neuropsychological testing will be useful in patients who report significant memory impairment or problems in attention or concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few case reports of treatment for patients with IEI symptoms and no controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3\">",
"     3",
"    </a>",
"    ]. Selection of treatment is largely based upon evidence from studies of somatoform disorders. Psychotherapy is the primary treatment and pharmacotherapy may be used as adjunctive treatment for certain symptoms such as anxiety or insomnia.",
"   </p>",
"   <p>",
"    Clinicians should focus on relief of symptoms and improving occupational and interpersonal functioning. Another aim of treatment is to help the patient understand the cause of the symptoms as less rooted in the environment and centered more on psychiatric issues, but this is not possible for all patients. In addition, it is not clear that the success of psychotherapy depends upon whether patients relinquish their belief that IEI is due to toxic causes.",
"   </p>",
"   <p>",
"    Identified psychiatric disorders such as major depression, dysthymia, or panic disorder should be treated with medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     General principles for clinical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our clinical experience, there are many general principles for guiding clinical management of vague, nonspecific, medically unexplained symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1,3,14,60,78\">",
"     1,3,14,60,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Schedule regular visits",
"     </li>",
"     <li>",
"      Establish a therapeutic alliance with the patient",
"     </li>",
"     <li>",
"      Acknowledge and legitimize symptoms",
"     </li>",
"     <li>",
"      Limit diagnostic testing and referrals to specialists",
"     </li>",
"     <li>",
"      Provide consistent, limited reassurance that grave medical diseases have been ruled out",
"     </li>",
"     <li>",
"      Provide psychoeducation about coping with symptoms of IEI",
"     </li>",
"     <li>",
"      Make functional improvement the goal of treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should schedule regular appointments at a frequency that mitigates the occurrence of crises and urgent telephone calls or visits.",
"   </p>",
"   <p>",
"    A patient's belief in chemical sensitivity and IEI will generally be long-standing and firmly held. Patients with IEI symptoms also feel their mainstream physicians do not understand them or take their complaints seriously [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. Thus, the clinician should refrain from directly challenging the patient's belief in IEI and avoid undermining the relationship with the patient.",
"   </p>",
"   <p>",
"    Patients diagnosed with a psychiatric illness can be informed that their condition is most likely treatable, especially mood and anxiety disorders. Clinicians should assure patients that the presence of a psychiatric disorder does not negate the reality of their suffering and is not so much the cause of the IEI symptoms, but rather, the psychiatric disorder is exacerbating and perpetuating the IEI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/60\">",
"     60",
"    </a>",
"    ]. This approach may facilitate the patient's acceptance of a formal psychiatric intervention. Patients may nevertheless react defensively if clinicians raise the possibility that there is psychopathology that needs to be addressed and treated.",
"   </p>",
"   <p>",
"    Some patients will refuse to work with clinicians unless they view IEI as a distinct, valid medical entity. Clinicians need not collude with such patients, and should take a long-term perspective and inform them that the clinician is always available to provide treatment when the patient is ready.",
"   </p>",
"   <p>",
"    Clinicians should emphasize the restoration and maintenance of functioning at work, home, and in social circles and deemphasize curing and eliminating symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/60\">",
"     60",
"    </a>",
"    ]. Clinicians should discourage patients from assuming the sick role and instead, patients should take an active role in treatment by setting and working on specific, realistic, incremental goals that include observable behaviors. One example is a graduated exercise program.",
"   </p>",
"   <p>",
"    Treatment recommendations depend upon the extent of the patient's illness belief and degree of impairment. Some patients will be interested only in specific treatment for a specified disorder, such as antidepressant medication for depression. Other patients may be receptive to entering a formal behavior modification program to improve their social and occupational functioning.",
"   </p>",
"   <p>",
"    Although many patients with IEI may be pursuing workmen's compensation or some other benefit, proper treatment extends beyond the recognition that patients may be malingering [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/1,22\">",
"     1,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several forms of psychotherapy can be used depending upon the patient's motivation and insight. These include behavioral desensitization, cognitive behavioral therapy, psychoeducation, supportive therapy, stress management, biofeedback, and psychodynamic psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/43\">",
"     43",
"    </a>",
"    ]. These can be provided individually or in a group format. Some clinicians use a variety of approaches, which in one case series resulted in improved functioning in nearly 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for short-term psychotherapy in patients with IEI symptoms include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clearly explain the structure of the treatment plan",
"     </li>",
"     <li>",
"      Teach meaningful skills relevant to daily life",
"     </li>",
"     <li>",
"      Training in these skills should continue until they are mastered in the therapist's office",
"     </li>",
"     <li>",
"      Patients should practice these skills outside of the office",
"     </li>",
"     <li>",
"      Clinicians should encourage the patient to attribute improvement to the patient's increased skills",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Behavioral desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;This treatment is based upon a behavioral model of the etiology of IEI. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    above.) A review suggests desensitization and graduated exposure can extinguish maladaptive responses to odors or other triggers in patients with IEI symptoms, and help patients overcome avoidance behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/14\">",
"     14",
"    </a>",
"    ]. One report described the successful use of desensitization in two patients who remained nearly symptom-free for several years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desensitization involves patients exposing themselves to odors and fumes found in typical home and work situations. Exposure begins with relatively benign odors and progresses to increasingly noxious stimuli. In addition, the frequency and quantity of exposure are gradually increased as treatment progresses. Exposure is conducted in the clinician's office initially, followed by self-exposure homework in the natural environment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/82\">",
"     82",
"    </a>",
"    ]. Treatment may be condensed into five consecutive days for two hours on each day, or spread out over several weeks. Desensitization is often incorporated as part of cognitive behavioral therapy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Cognitive behavioral therapy (CBT)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cognitive behavioral therapy (CBT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled trials have tested the efficacy of CBT specifically for patients with IEI symptoms. However, systematic reviews have found CBT was efficacious for treatment of somatoform disorders and medically unexplained symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Furthermore, there was more evidence to support the use of cognitive behavioral therapy than any other intervention. The behavioral techniques include response prevention, systematic desensitization, progressive muscle relaxation, and graduated exercise programs (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Behavioral desensitization'",
"    </a>",
"    above)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of 31 controlled trials of CBT for patients with somatoform disorders found that in 71 percent of the studies, physical symptoms improved significantly more in the CBT patients than the controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/85\">",
"     85",
"    </a>",
"    ]. Psychologic distress improved significantly more in CBT patients in 38 percent of the studies, and functioning improved significantly more in 47 percent of the studies.",
"   </p>",
"   <p>",
"    A practical guide for providing CBT is available (",
"    <a class=\"graphic graphic_table graphicRef73567 \" href=\"UTD.htm?22/33/23069\">",
"     table 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/14,86\">",
"     14,86",
"    </a>",
"    ]. The use of CBT is limited by an inability to rationally discuss cognitive distortions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Family therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involving family members in treatment can help clinicians better understand the patient's symptoms, and address how family members unintentionally reinforce the patient's problematic behaviors. Difficulties with specific family functions and processes such as communication and problem solving may also exacerbate the patient's illness. In addition, family members may be struggling to cope with the patient's illness and may require help for themselves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few individual case reports that adjunctive selective serotonin reuptake inhibitors may be helpful for treating IEI symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/87-89\">",
"     87-89",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     Citalopram",
"    </a>",
"    60 mg per day or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    20 to 40 mg per day was successfully used to treat patients with IEI symptoms plus a depressive or anxiety disorder. Good results persisted for six months to four years during maintenance treatment. However, the United States Food and Drug Administration issued warnings that citalopram causes dose-dependent QT interval prolongation that can lead to arrhythmias, and thus recommends that the maximum dose should not exceed 40 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Additional information about the citalopram warnings and cardiac effects of SSRIs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, systematic reviews of controlled trials for treatment of somatoform disorders (including undifferentiated somatoform disorder) and medically unexplained symptoms have found evidence to support the use of antidepressant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. A meta-analysis of 94 controlled trials compared antidepressants to placebo and nonantidepressant medications, and found a large clinical effect with antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/92\">",
"     92",
"    </a>",
"    ]. As an example, one study found significantly more patients responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    (12.5 to 37.5 mg two hours before bedtime) than placebo (74 versus 49 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with IEI symptoms may resist taking \"chemicals\" to treat their psychiatric disorders and others will report intolerance to relatively low levels of medication. Doses of psychotropic agents should start low and be increased slowly as tolerated to achieve a therapeutic dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Unproven therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variety of treatments dispensed by clinical ecologists is limited only by their imagination and resourcefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/25\">",
"     25",
"    </a>",
"    ]. These include avoidance of chemicals, environment changes, special diets, over-the-counter or prescribed medications, sublingual ingestion or subcutaneous injection of small doses of an alleged offending chemical, and detoxification procedures. Some interventions cause iatrogenic effects and can seriously disrupt the lives of patients. There is no justification for these treatments.",
"   </p>",
"   <p>",
"    A survey of over 900 people with self-reported IEI, published in 2003, counted more than 100 types of commonly used treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients spent a mean total of 7000 US dollars on treatments in the prior year, accounting for 15 percent of household income. The mean number of treatments ever tried for patients with mild IEI was 25 and for those with severe IEI was 33. The treatments most highly rated by patients were creating a chemical-free living space, avoiding chemicals, and prayer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the information on the natural history of IEI comes from follow-up studies lasting less than three years. These data indicate that the condition is highly stable and most patients remain chronically ill. A prospective study of 49 patients with IEI symptoms found that 92 percent remained ill after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/76,94\">",
"     76,94",
"    </a>",
"    ]. In addition, patients reported significantly more somatic symptoms than a control group at baseline and at 32 months post baseline. Other studies have found that 54 to 96 percent of patients with IEI symptoms were unchanged or worse when they were reassessed several months to two years after their initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/18,22\">",
"     18,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study conducted at an occupational health clinic found that a longer elapsed time from onset of IEI symptoms until the first clinic appointment was significantly associated with a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Greater rates of improvement may occur over longer periods of time. A psychiatrist interviewed 18 patients with IEI symptoms nine years after their initial interview, and rated 2 patients as remitted, 14 as improved, and 2 as unchanged or worse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/38/27242/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Whereas all 18 patients were initially in treatment with a clinical ecologist, only 7 were at the time of follow-up. However, all 18 remained convinced that IEI was a valid medical entity, and they continued to have problems with somatization, obsessive-compulsiveness, and hypochondriasis.",
"   </p>",
"   <p>",
"    There are no data on the rate of recurrence among patients who recover from symptoms of IEI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic environmental intolerance (IEI) or multiple chemical sensitivity is a subjective illness marked by recurrent, vague, nonspecific symptoms attributed to low levels of chemical, biologic, or physical agents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IEI is not a distinct, valid medical entity. Symptoms lack specificity, there is no reliable case definition or set of diagnostic criteria, and there are no consistent objective diagnostic physical findings or laboratory tests. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with IEI symptoms undergo unorthodox diagnostic tests and unproven and potentially harmful treatments by clinicians who refer to themselves as clinical ecologists or environmental clinicians. &nbsp;(See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimates of the prevalence of IEI vary widely. Self-reported chemical sensitivity is found in 9 to 33 percent of the general population. IEI symptoms are more common in women. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different hypotheses regarding the etiology of IEI involve learned behavior, anxiety, classic and operant conditioning, symptom amplification, and skewed cognitive processing. None of these are mutually exclusive. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with IEI symptoms have one or more psychiatric disorders that predate the onset of IEI symptoms. The most frequently identified psychiatric illnesses are somatoform, mood, and anxiety disorders. The clinical features of IEI often resemble the specific diagnosis of undifferentiated somatoform disorder. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Psychiatric diagnoses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history conducted as part of the medical evaluation should include questions about occupational and environmental exposure. The evaluation should attempt to exclude objectively defined physical illnesses. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Medical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A brief screening instrument can be used to assess patients for psychiatric disorders. The Primary Care Evaluation of Mental Disorders Patient Health Questionnaire screens for and provides categorical DSM-IV diagnoses for somatoform, depressive, and anxiety disorders. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Psychiatric assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many general principles for guiding clinical management of vague, nonspecific, medically unexplained symptoms. These include scheduling regular visits, establishing a therapeutic alliance, acknowledging symptoms and not challenging the patient's beliefs regarding IEI, evaluating and treating patients for diagnosable medical diseases including psychiatric disorders, limiting diagnostic tests and referrals to specialists, providing limited reassurance that grave medical diseases have been ruled out, and providing psychoeducation about IEI. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'General principles for clinical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for patients with IEI symptoms is largely based upon evidence from studies of somatoform disorders. Clinicians should focus upon relieving symptoms rather than curing them, and improving occupational and interpersonal functioning. In patients with IEI who are amenable to treatment, we suggest psychotherapy as the primary option (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients who are unwilling to undergo psychotherapy but willing to accept medications, treatment with antidepressants is a reasonable alternative.",
"     </li>",
"     <li>",
"      A number of forms of psychotherapy have been tried. We suggest cognitive behavioral therapy (CBT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives include behavioral desensitization and family therapy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Cognitive behavioral therapy (CBT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients being treated with CBT, we suggest additionally treating with antidepressants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IEI is highly stable and most patients remain ill with impaired occupational and social functioning during follow-up studies that last one to three years. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/1\">",
"      ACOEM position statement. Multiple chemical sensitivities: idiopathic environmental intolerance. College of Occupational and Environmental Medicine. J Occup Environ Med 1999; 41:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/2\">",
"      Idiopathic environmental intolerances. American Academy of Allergy, Asthma and Immunology (AAAAI) Board of Directors. J Allergy Clin Immunol 1999; 103:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/3\">",
"      Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: review. Curr Opin Otolaryngol Head Neck Surg 2007; 15:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/4\">",
"      Bornschein S, Hausteiner C, Zilker T, F&ouml;rstl H. Psychiatric and somatic disorders and multiple chemical sensitivity (MCS) in 264 'environmental patients'. Psychol Med 2002; 32:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/5\">",
"      Levin AS, Byers VS. Environmental illness: a disorder of immune regulation. Occup Med 1987; 2:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/6\">",
"      Meggs WJ, Dunn KA, Bloch RM, et al. Prevalence and nature of allergy and chemical sensitivity in a general population. Arch Environ Health 1996; 51:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/7\">",
"      Miller CS. White paper: Chemical sensitivity: history and phenomenology. Toxicol Ind Health 1994; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/8\">",
"      International Programme on Chemical Safety (IPCS). Conclusions and recommendations of a workshop on \"multiple chemical sensitivities (MCS)\". Regul Toxicol Pharmacol 1996; 24:S188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/9\">",
"      Black DW. Environmental illness and misdiagnosis--a growing problem. Regul Toxicol Pharmacol 1993; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/10\">",
"      American Academy of Allergy: position statements--controversial techniques. J Allergy Clin Immunol 1981; 67:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/11\">",
"      Clinical ecology. Executive Committee of the American Academy of Allergy and Immunology. J Allergy Clin Immunol 1986; 78:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/12\">",
"      Clinical ecology. American College of Physicians. Ann Intern Med 1989; 111:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/13\">",
"      Clinical ecology. Council on Scientific Affairs, American Medical Association. JAMA 1992; 268:3465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/14\">",
"      Bornschein S, F&ouml;rstl H, Zilker T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med 2001; 250:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/15\">",
"      Hausteiner C, Bornschein S, Hansen J, et al. Self-reported chemical sensitivity in Germany: a population-based survey. Int J Hyg Environ Health 2005; 208:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/16\">",
"      Kreutzer R, Neutra RR, Lashuay N. Prevalence of people reporting sensitivities to chemicals in a population-based survey. Am J Epidemiol 1999; 150:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/17\">",
"      Caress SM, Steinemann AC. Prevalence of multiple chemical sensitivities: a population-based study in the southeastern United States. Am J Public Health 2004; 94:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/18\">",
"      Lax MB, Henneberger PK. Patients with multiple chemical sensitivities in an occupational health clinic: presentation and follow-up. Arch Environ Health 1995; 50:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/19\">",
"      Bell IR, Peterson JM, Schwartz GE. Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. J Clin Psychiatry 1995; 56:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/20\">",
"      Brodsky CM. 'Allergic to everything': a medical subculture. Psychosomatics 1983; 24:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/21\">",
"      Stewart DE, Raskin J. Psychiatric assessment of patients with \"20th-century disease\" (\"total allergy syndrome\"). CMAJ 1985; 133:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/22\">",
"      Terr AI. Environmental illness. A clinical review of 50 cases. Arch Intern Med 1986; 146:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/23\">",
"      Terr, AI. Multiple chemical sensitivity syndrome. Occup Asthma Allergies 1992;12:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/24\">",
"      Simon GE, Katon WJ, Sparks PJ. Allergic to life: psychological factors in environmental illness. Am J Psychiatry 1990; 147:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/25\">",
"      Black DW, Rathe A, Goldstein RB. Environmental illness. A controlled study of 26 subjects with '20th century disease'. JAMA 1990; 264:3166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/26\">",
"      Black DW, Rathe A, Goldstein RB. Measures of distress in 26 \"environmentally ill\" subjects. Psychosomatics 1993; 34:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/27\">",
"      Simon GE, Daniell W, Stockbridge H, et al. Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. A controlled study. Ann Intern Med 1993; 119:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/28\">",
"      Fiedler N, Maccia C, Kipen H. Evaluation of chemically sensitive patients. J Occup Med 1992; 34:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/29\">",
"      Fiedler N, Kipen HM, DeLuca J, et al. A controlled comparison of multiple chemical sensitivities and chronic fatigue syndrome. Psychosom Med 1996; 58:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/30\">",
"      Black DW. Iatrogenic (physician-induced) hypochondriasis. Four patient examples of \"chemical sensitivity\". Psychosomatics 1996; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/31\">",
"      Bailer J, Witth&ouml;ft M, Paul C, et al. Evidence for overlap between idiopathic environmental intolerance and somatoform disorders. Psychosom Med 2005; 67:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/32\">",
"      Bailer J, Witth&ouml;ft M, Rist F. Modern health worries and idiopathic environmental intolerance. J Psychosom Res 2008; 65:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/33\">",
"      Eis D, Helm D, M&uuml;hlinghaus T, et al. The German Multicentre Study on Multiple Chemical Sensitivity (MCS). Int J Hyg Environ Health 2008; 211:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/34\">",
"      Hausteiner C, Bornschein S, Bickel H, et al. Psychiatric morbidity and low self-attentiveness in patients with environmental illness. J Nerv Ment Dis 2003; 191:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/35\">",
"      Hausteiner C, Mergeay A, Bornschein S, et al. New aspects of psychiatric morbidity in idiopathic environmental intolerances. J Occup Environ Med 2006; 48:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/36\">",
"      Poonai N, Antony MM, Binkley KE, et al. Carbon dioxide inhalation challenges in idiopathic environmental intolerance. J Allergy Clin Immunol 2000; 105:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/37\">",
"      Black DW, Doebbeling BN, Voelker MD, et al. Multiple chemical sensitivity syndrome: symptom prevalence and risk factors in a military population. Arch Intern Med 2000; 160:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/38\">",
"      Gibson PR, Elms AN, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity. Environ Health Perspect 2003; 111:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/39\">",
"      Staudenmayer H, Phillips S. MMPI-2 validity, clinical and content scales, and the Fake Bad Scale for personal injury litigants claiming idiopathic environmental intolerance. J Psychosom Res 2007; 62:61.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/41\">",
"      Gots RE. Multiple chemical sensitivities: distinguishing between psychogenic and toxicodynamic. Regul Toxicol Pharmacol 1996; 24:S8.",
"     </a>",
"    </li>",
"    <li>",
"     Journal of Toxicology and Environmental Health, Part A 2008; 71:766.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/43\">",
"      Staudenmayer H. Psychological treatment of psychogenic idiopathic environmental intolerance. Occup Med 2000; 15:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/44\">",
"      Black DW. The relationship of mental disorders and idiopathic environmental intolerance. Occup Med 2000; 15:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/45\">",
"      Staudenmayer H, Binkley KE, Leznoff A, Phillips S. Idiopathic environmental intolerance: Part 1: A causation analysis applying Bradford Hill's criteria to the toxicogenic theory. Toxicol Rev 2003; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/46\">",
"      Staudenmayer H, Binkley KE, Leznoff A, Phillips S. Idiopathic environmental intolerance: Part 2: A causation analysis applying Bradford Hill's criteria to the psychogenic theory. Toxicol Rev 2003; 22:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/47\">",
"      Staudenmayer H. Idiopathic environmental intolerances (IEI): myth and reality. Toxicol Lett 2001; 120:333.",
"     </a>",
"    </li>",
"    <li>",
"     Bell, IR. Neuropsychiatric and biopsychosocial mechanisms in multiple chemical sensitivity: an olfactory-limbic system model. In: Multiple Chemical Sensitivities, National Academy Press, Washington DC 1992. p.89.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/49\">",
"      Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: A systematic review of provocation studies. J Allergy Clin Immunol 2006; 118:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/50\">",
"      Bornschein S, Hausteiner C, R&ouml;mmelt H, et al. Double-blind placebo-controlled provocation study in patients with subjective Multiple Chemical Sensitivity (MCS) and matched control subjects. Clin Toxicol (Phila) 2008; 46:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/51\">",
"      Heuser G, Mena I, Alamos F. NeuroSPECT findings in patients exposed to neurotoxic chemicals. Toxicol Ind Health 1994; 10:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/52\">",
"      Bell IR, Schwartz GE, Hardin EE, et al. Differential resting quantitative electroencephalographic alpha patterns in women with environmental chemical intolerance, depressives, and normals. Biol Psychiatry 1998; 43:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/53\">",
"      Black DW, Okiishi C, Gabel J, Schlosser S. Psychiatric illness in the first-degree relatives of persons reporting multiple chemical sensitivities. Toxicol Ind Health 1999; 15:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/54\">",
"      Bornschein S, Hausteiner C, Konrad F, et al. Psychiatric morbidity and toxic burden in patients with environmental illness: a controlled study. Psychosom Med 2006; 68:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/55\">",
"      Leznoff A. Provocative challenges in patients with multiple chemical sensitivity. J Allergy Clin Immunol 1997; 99:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/56\">",
"      Binkley KE, Kutcher S. Panic response to sodium lactate infusion in patients with multiple chemical sensitivity syndrome. J Allergy Clin Immunol 1997; 99:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/57\">",
"      Amundsen MA, Hanson NP, Bruce BK, et al. Odor aversion of multiple chemical sensitivities: recommendation for a name change and description of successful behavioral medicine treatment. Regul Toxicol Pharmacol 1996; 24:S116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/58\">",
"      Binkley K, King N, Poonai N, et al. Idiopathic environmental intolerance: increased prevalence of panic disorder-associated cholecystokinin B receptor allele 7. J Allergy Clin Immunol 2001; 107:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/59\">",
"      Bolla-Wilson K, Wilson RJ, Bleecker ML. Conditioning of physical symptoms after neurotoxic exposure. J Occup Med 1988; 30:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/60\">",
"      Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med 1999; 130:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/61\">",
"      Lorber W, Mazzoni G, Kirsch I. Illness by suggestion: expectancy, modeling, and gender in the production of psychosomatic symptoms. Ann Behav Med 2007; 33:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/62\">",
"      Dalton P. Cognitive influences on health symptoms from acute chemical exposure. Health Psychol 1999; 18:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/63\">",
"      Hausteiner C, Bornschein S, Zilker T, et al. Dysfunctional cognitions in idiopathic environmental intolerances (IEI)--an integrative psychiatric perspective. Toxicol Lett 2007; 171:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/64\">",
"      Witth&ouml;ft M, Gerlach AL, Bailer J. Selective attention, memory bias, and symptom perception in idiopathic environmental intolerance and somatoform disorders. J Abnorm Psychol 2006; 115:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/65\">",
"      Witth&ouml;ft M, Rist F, Bailer J. Abnormalities in cognitive-emotional information processing in idiopathic environmental intolerance and somatoform disorders. J Behav Ther Exp Psychiatry 2009; 40:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/66\">",
"      Staudenmayer H, Selner ME, Selner JC. Adult sequelae of childhood abuse presenting as environmental illness. Ann Allergy 1993; 71:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/67\">",
"      Bailer J, Witth&ouml;ft M, Bayerl C, Rist F. Trauma experience in individuals with idiopathic environmental intolerance and individuals with somatoform disorders. J Psychosom Res 2007; 63:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/68\">",
"      Ford CV. Somatization and fashionable diagnoses: illness as a way of life. Scand J Work Environ Health 1997; 23 Suppl 3:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/69\">",
"      Bornschein S, Hausteiner C, Drzezga A, et al. Neuropsychological and positron emission tomography correlates in idiopathic environmental intolerances. Scand J Work Environ Health 2007; 33:447.",
"     </a>",
"    </li>",
"    <li>",
"     Rea, WJ, Johnson, AR, Ross, GH , et al. Considerations for the diagnosis of chemical sensitivity. In: Multiple Chemical Sensitivities, National Academy Press, Washington DC1992. p.169.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/71\">",
"      Cullen MR. The worker with multiple chemical sensitivities: an overview. Occup Med 1987; 2:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/72\">",
"      Jewett DL, Fein G, Greenberg MH. A double-blind study of symptom provocation to determine food sensitivity. N Engl J Med 1990; 323:429.",
"     </a>",
"    </li>",
"    <li>",
"     Heuser, G, Wojdani, A, Heuser, S. Diagnostic markers of multiple chemical sensitivity. In: Multiple Chemical Sensitivities, National Academy Press, Washington DC 1992. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/74\">",
"      Poonai NP, Antony MM, Binkley KE, et al. Psychological features of subjects with idiopathic environmental intolerance. J Psychosom Res 2001; 51:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/75\">",
"      Tohen M, Bromet E, Murphy JM, Tsuang MT. Psychiatric epidemiology. Harv Rev Psychiatry 2000; 8:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/76\">",
"      Bailer J, Witth&ouml;ft M, Bayerl C, Rist F. Syndrome stability and psychological predictors of symptom severity in idiopathic environmental intolerance and somatoform disorders. Psychol Med 2007; 37:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/77\">",
"      Sparks PJ, Daniell W, Black DW, et al. Multiple chemical sensitivity syndrome: a clinical perspective. I. Case definition, theories of pathogenesis, and research needs. J Occup Med 1994; 36:718.",
"     </a>",
"    </li>",
"    <li>",
"     Yutzy, SH, Parish, BS. Somatoform disorders. In: The American Psychiatric Publishing Textbook of Psychiatry, 5th ed, Hales, RE, Yudofsky, SC, Gabbard, GO (Ed), American Psychiatric Publishing, Washington, DC 2008. p.618.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/79\">",
"      Salvaggio JE. Clinical and immunologic approach to patients with alleged environmental injury. Ann Allergy 1991; 66:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/80\">",
"      Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/81\">",
"      Staudenmayer H. Clinical consequences of the EI/MCS \"diagnosis\": two paths. Regul Toxicol Pharmacol 1996; 24:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/82\">",
"      Guglielmi RS, Cox DJ, Spyker DA. Behavioral treatment of phobic avoidance in multiple chemical sensitivity. J Behav Ther Exp Psychiatry 1994; 25:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/83\">",
"      Sumathipala A. What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosom Med 2007; 69:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/84\">",
"      Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/85\">",
"      Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom 2000; 69:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/86\">",
"      Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional somatic symptoms: a practical guide. J Psychosom Res 1992; 36:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/87\">",
"      Stenn P, Binkley K. Successful outcome in a patient with chemical sensitivity. Treatment with psychological desensitization and selective serotonin reuptake inhibitor. Psychosomatics 1998; 39:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/88\">",
"      Black DW. Paroxetine for multiple chemical sensitivity syndrome. Am J Psychiatry 2002; 159:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/89\">",
"      Andin&eacute; P, R&ouml;nnb&auml;ck L, J&auml;rvholm B. Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities. Acta Psychiatr Scand 1997; 96:82.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). file://www.fda.gov/Drugs/DrugSafety/ucm269086.htm (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses file://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/92\">",
"      O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/93\">",
"      Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998; 37:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/94\">",
"      Bailer J, Witth&ouml;ft M, Rist F. Psychological predictors of short- and medium term outcome in individuals with idiopathic environmental intolerance (IEI) and individuals with somatoform disorders. J Toxicol Environ Health A 2008; 71:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/95\">",
"      Black DW, Okiishi C, Schlosser S. A nine-year follow-up of people diagnosed with multiple chemical sensitivities. Psychosomatics 2000; 41:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/38/27242/abstract/96\">",
"      Black DW, Okiishi C, Schlosser S. The Iowa follow-up of chemically sensitive persons. Ann N Y Acad Sci 2001; 933:48.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7764 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27242=[""].join("\n");
var outline_f26_38_27242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Health care utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychosocial functioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887502\">",
"      Toxicogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887516\">",
"      Psychogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887533\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887550\">",
"      Conditioned response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887562\">",
"      Symptom amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887578\">",
"      Iatrogenic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887613\">",
"      Cognitive processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887597\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2887585\">",
"      Coping mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chemical exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CASE DEFINITIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Unvalidated testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PSYCHIATRIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychiatric diagnoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Somatoform disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mood and anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Psychiatric distress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MEDICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laboratory and medical tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Psychiatric assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      General principles for clinical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Behavioral desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cognitive behavioral therapy (CBT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Family therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Unproven therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7764|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/35/5692\" title=\"table 1\">",
"      Common symptoms IEI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/0/7179\" title=\"table 2\">",
"      Cullens definition IEI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/21/37213\" title=\"table 3\">",
"      Lifetime psych dx IEI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/27/23995\" title=\"table 4\">",
"      DSM undiff somatoform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/54/14188\" title=\"table 5\">",
"      Medical eval IEI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/32/22019\" title=\"table 6\">",
"      PHQ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/33/23069\" title=\"table 7\">",
"      Practical guide CBT IEI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=related_link\">",
"      Primary care management of medically unexplained symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_38_27243="Fibrinogen disorders";
var content_f26_38_27243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of fibrinogen disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Quantitative abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Afibrinogenemia (uncommon, autosomal recessive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypofibrinogenemia (autosomal dominant)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypofibrinogenemia (eg, consumptive coagulopathies, liver disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperfibrinogenemia (eg, inflammation, neoplasia, pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medications (eg, fibrinolytic agents, L-asparaginase, valproic acid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Qualitative abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysfibrinogenemia (autosomal dominant)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypodysfibrinogenemia (autosomal dominant)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignancies (eg, renal carcinoma, hepatoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antifibrinogen antibodies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27243=[""].join("\n");
var outline_f26_38_27243=null;
var title_f26_38_27244="Cultivable flora oral cavity";
var content_f26_38_27244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predominant cultivable flora from various sites of the oral cavity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Group",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Predominant genus or family",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"       Total viable count (mean percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Tongue",
"      </td>",
"      <td class=\"subtitle2\">",
"       Saliva",
"      </td>",
"      <td class=\"subtitle2\">",
"       Gingival crevice",
"      </td>",
"      <td class=\"subtitle2\">",
"       Dental plaque",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"       Anaerobes (1011 CFU/g)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gram + cocci",
"      </td>",
"      <td>",
"       Peptostreptococcus",
"      </td>",
"      <td>",
"       4.2",
"      </td>",
"      <td>",
"       13.0",
"      </td>",
"      <td>",
"       7.4",
"      </td>",
"      <td>",
"       13.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Gram - cocci, Gram + rods",
"      </td>",
"      <td>",
"       Veillonella",
"      </td>",
"      <td>",
"       16.0",
"      </td>",
"      <td>",
"       15.9",
"      </td>",
"      <td>",
"       10.7",
"      </td>",
"      <td>",
"       6.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Actinomyces, Eubacterium, Lactobacillus, Leptotrichia",
"      </td>",
"      <td>",
"       7.4",
"      </td>",
"      <td>",
"       4.8",
"      </td>",
"      <td>",
"       20.2",
"      </td>",
"      <td>",
"       18.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gram - rods",
"      </td>",
"      <td>",
"       Fusobacterium, Bacteroides, Prevotella, Porphyromonas",
"      </td>",
"      <td>",
"       8.2",
"      </td>",
"      <td>",
"       4.8",
"      </td>",
"      <td>",
"       16.1",
"      </td>",
"      <td>",
"       10.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"       Aerobes (1010 CFU/g)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gram + cocci",
"      </td>",
"      <td>",
"       Streptococcus",
"      </td>",
"      <td>",
"       44.8",
"      </td>",
"      <td>",
"       46.2",
"      </td>",
"      <td>",
"       28.8",
"      </td>",
"      <td>",
"       28.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gram - cocci",
"      </td>",
"      <td>",
"       Moraxella",
"      </td>",
"      <td>",
"       3.4",
"      </td>",
"      <td>",
"       1.2",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gram + rods",
"      </td>",
"      <td>",
"       Lactobacillus, Corynebacterium",
"      </td>",
"      <td>",
"       13.0",
"      </td>",
"      <td>",
"       11.8",
"      </td>",
"      <td>",
"       15.3",
"      </td>",
"      <td>",
"       24.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gram - rods",
"      </td>",
"      <td>",
"       Enterobacteriaceae",
"      </td>",
"      <td>",
"       3.2",
"      </td>",
"      <td>",
"       2.3",
"      </td>",
"      <td>",
"       1.2",
"      </td>",
"      <td>",
"       Not done",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Total viable colony-forming units per g net weight.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Chow, AW, Roser, SM, Brady, FA, Ann Intern Med 1978; 88:392.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27244=[""].join("\n");
var outline_f26_38_27244=null;
var title_f26_38_27245="Contents: Gastroenterology";
var content_f26_38_27245=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gastroenterology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gastroenterology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/14/35048\">",
"           Constipation in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/22/13673\">",
"           Etiology and evaluation of chronic constipation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/59/22458\">",
"           Fecal incontinence in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/56/27530\">",
"           Lymphocytic and collagenous colitis (microscopic colitis)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-4BA27F15CD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_38_27245=[""].join("\n");
var outline_f26_38_27245=null;
var title_f26_38_27246="Amiodarone in CAMIAT";
var content_f26_38_27246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Effect of amiodarone in CAMIAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 511px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of amiodarone versus placebo in 1202 postmyocardial infarction patients with ventricular ectopy in the CAMIAT trial. By an intention to treat analysis, amiodarone produced a significant reduction in arrhythmic death (top panel, p = 0.016) but no change in all-cause mortality (bottom panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cairns JA, Connolly SJ, Gent M, et al. Lancet 1997; 349:675.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27246=[""].join("\n");
var outline_f26_38_27246=null;
var title_f26_38_27247="Keloid morphea";
var content_f26_38_27247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Keloid morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keloid morphea can be single or multiple and are generally several centimeters in diameter. The plaque is indurated and resembles a post-traumatic scar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francesco Zulian, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_38_27247=[""].join("\n");
var outline_f26_38_27247=null;
